Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy

**Anik Banik¹, Sheikh Rashel Ahmed², Emran Hossain Sajib¹, Anamika Deb¹, Shiuly Sinha¹,
Kazi Faizul Azim^{1,3,4*}**

¹*Faculty of Biotechnology and Genetic Engineering, Sylhet Agricultural University, Sylhet-3100, Bangladesh*

²*Department of Plant and Environmental Biotechnology, Sylhet Agricultural University, Sylhet-3100, Bangladesh*

³*Department of Microbial Biotechnology, Sylhet Agricultural University, Sylhet, 3100, Bangladesh*

⁴*Faculty of Pharmacy, Universite de Tours, Tours 37200, France.*

Abbreviations: MTA, Metastasis Tumor Antigen; LD50, Lethal dose 50; ADME, Absorption, distribution, metabolism, and excretion; BBB, Blood brain barrier.

***Corresponding author at:** Department of Microbial Biotechnology, Sylhet Agricultural University, Sylhet, 3100, Bangladesh.

Faculty of Pharmacy, Universite de Tours, Tours 37200, France

E-mail: faizulazim22@outlook.com; kazifaizul.azim@etu.univ-tours.fr

ORCID ID: <https://orcid.org/0000-0001-9613-6559>

Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy

Abstract

The deeper understanding of metastasis phenomenon and detection of drug targets could be a potential approach to minimize cancer mortality. In this study, attempts were taken to unmask novel therapeutics to prevent metastasis and cancer progression. Initially, we explored the physiochemical, structural and functional insights of three metastasis tumor antigens (MTAs) and evaluated some plant based bioactive compounds as potent MTA inhibitors. From 50 plant metabolites screened, isoflavone, gingerol, citronellal and asiatic acid showed maximum binding affinity with all three MTA proteins. The ADME analysis detected no undesirable toxicity that could reduce the drug likeness properties of top plant metabolites. Moreover, molecular dynamics studies revealed that the complexes were stable and showed minimum fluctuation at molecular level. We further performed ligand based virtual screening to identify similar drug molecules using a large collection of 3,76,342 compounds from DrugBank. The results suggested that several structural analogs (e.g. Tramadol, Nabumetone, DGLA, Hydrocortisone) may act as agonist to block the MTA proteins and inhibit cancer progression at early stage. The study could be useful to develop effective medications against cancer metastasis in future. Due to encouraging results, we highly recommend further *in vitro* and *in vivo* trials for the experimental validation of the findings.

Keywords: Metastasis tumor antigens (MTA), plant metabolites, ADME analysis, molecular dynamics, virtual screening, drug targets

1. Introduction

Diseases are clinical conditions which impairs normal functions and structures of an organism [1]. However, among various types of morbid diseases, cancer is the most dangerous one [2, 3]. Cancer is a disease that can be found in almost any tissue or organ when abnormal cells uncontrollably form. Gradually, tumor cells exceed their natural boundaries, invade neighboring body regions and become malignant. Millions of people have to die every year due to the severity of this disease and the disease becomes more severe when metastasis occurs [4]. The International Cancer Research Agency focused on the geographical variation across 20 regions of the world and estimated that there will be 18.1 million new cancer cases and 9.6 million cancer deaths in 2018 [5]. Lung cancer is the most frequently diagnosed cancer in both sexes (11.6% of total cases) and the leading cause of cancer mortality (18.4%), followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for prevalence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality [5]. Approximately 1,500 people continue to die from cancer each day, providing evidence for the inability to treat the disease as it spreads across the body [6].

Metastasis refers to the process by which the cancer cells migrate through the whole body [7]. Around 90% of cancer-related deaths are caused by metastasis of the initial tumor cells to locations away from the central or primary tumor [8]. The proteins of basal lamina are degraded by a mixture of digestive enzymes which secrets from cancer cells and allow it to crawl through. Matrix metalloproteases (MMP) are secreted by cancer cells which cut through the proteins that prevent migrating cancer cells from moving. Tumors can spread to distant organs be through the circulatory system, lymphatic system, and the body wall through the abdominal and chest cavities [9]. A variety of cancer-related genes and molecules have been identified which may lead to cancer progression. Among them the gene family MTA (Metastasis Tumor Antigen) plays a key role in cancer metastasis (Table 1) [10-18]. Gene products produced by MTA genes (i.e. MTA1, MTA2 and MTA3 protein) are closely related to the metastasis cycle [19, 20]. Various factors are regulated by MTA expression including growth factors, growth factor receptors, onco-genes, environmental stress, radiation, inflammation, and hypoxia [21, 22].

The founding member of MTA family, MTA1 is predominantly located in the nucleus and distributed in the extra-nuclear compartments as well [23]. MTA1 and its downstream

effectors regulate genes and/or pathways in cancer cells with roles in breast cancer development, invasion, survival, angiogenesis, epithelial-to-mesenchymal transfer, metastasis, DNA damage response and hormone-independence [24]. One of the key cancer promoting activities of MTA1 is its strong interaction with oncogenes in human cancer [25]. It stimulates the transcription of Stat3, breast cancer-amplified sequence 3 [26]. Thus MTA1 helps in cancer progression by inhibiting tumor suppressor genes and stimulating transcription of oncogenes. MTA2 protein is located inside the nucleus and acts in the mechanism chromatin remodeling to control the gene expression. It is over-expressed in human cancer cells and its level of dysregulation is well correlated with more invasive and aggressive phenotypes [27]. MTA2 deacetylates the estrogen receptor alpha and p53 and inhibits their trans-activation functions [28] and thus represses the genes of tumor suppressors and helps in cancer cell development. On the contrary, MTA3 protein locates both in the nucleus and other cellular compartments [29]. The protein controls the selection of targets for nucleosome remodeling and histone deacetylation, thus acting as a transcription repressor. Moreover, MTA family proteins play a key role in aging and Alzheimer's disease by controlling neuronal genes [30]. Chemical based therapies show various limitations such as drug-resistance, severe side effects, adverse toxicity profile for clinical applications [31, 32]. Natural products, on the other hand, have the potential to form the basis of holistic health care [33]. Due to the medicinal value various plant metabolites are used to treat life-threatening diseases (e.g. cancer, Alzheimer, diabetes, cardiac disease) (Table 2) and to minimize drug toxicity [34-74]. Computing methodologies have been an integral feature of many drug discovery projects, from hits to optimization and beyond. The de-novo detection of active compounds, without choice, can be achieved by virtual screening on protein models, separate from molecular similarity and ligand-based virtual screening [75]. Recent advances in the detection of new ligands and their receptor-bound structures as well as increased results for ligand discovery have rekindled interest in virtual screening that is still generally used for medicinal research [76]. Hence, the study was designed to evaluate some plant-based bioactive compounds and their synthetic analogs to reveal novel therapeutic options against cancer progression by utilizing virtual screening methods and various computational analyses.

2. Materials and methods

2.1. Retrieval of metastasis-associated proteins and plant metabolites

The UniProtKB protein database (www.uniprot.org/) was searched for the retrieval of the human metastasis-associated proteins MTA1 (Metastasis Tumor Antigen 1), MTA2 (Metastasis Tumor Antigen 2) and MTA3 (Metastasis Tumor Antigen 3). The proteins were further cross-checked in NCBI (<http://www.ncbi.nlm.nih.gov/>) protein database for the corresponding accession numbers. Besides, a total of 50 plant metabolites belonging to different classes were retrieved from PubChem server in SDS (3D) format [77]. OpenBabel v2.3 software was used to convert the structures into PDB format [78, 79].

2.2. Analysis of physicochemical properties and sub-cellular localization

Various physicochemical properties of the MTA proteins were demonstrated using ProtParam, a tool from ExPASy server [80]. Molecular weight, theoretical pI, extinction co-efficient, grand average of hydropathy (GRAVY), half-life, aliphatic index (AI), instability index and amino acid composition were calculated. For understanding protein function, it is important to find out the sub-cellular localization of proteins. CELLO [81], ngLOC [82] and PSIPred [83] servers were used for this purpose.

2.3. Secondary structure prediction and functional analysis

Secondary structures, the conformation that is adopted by the polypeptide backbone of a protein, are composed of regions stabilized by hydrogen bonds between different atoms [84]. Different secondary structural elements (e.g. helices, pleated sheets, turns) were analyzed using CFSSP (Chou and Fasman secondary structure prediction) server [85] and PSIPRED (PSI-blast based secondary structure prediction) tools [86]. Families and super-families of the MTA proteins were analyzed using SUPERFAMILY v2.0 [87, 88]. Moreover, NCBI-CDD (NCBI Conserved Domains Database), a protein annotation resource of NCBI [89] and MOTIF Search server [90] determined the conserved domains and motifs of these proteins, respectively.

2.4. Tertiary structure prediction, refinement and validation

All three proteins (i.e. MTA1, MTA2, MTA3) were subjected to 3D modeling via I-TASSER (Iterative Threading Assembly Refinement) through using a hierarchical protein structure prediction approach [91]. The unwanted errors in the predicted models were removed by GalaxyRefine service of GalaxyWEB server [92]. The best refined models of the studied proteins were determined through quality assessment and validation. Commonly used tools, ERRAT [93] and RAMPAGE [94] were employed to meet this purpose. The SAVES v5.0 (<https://servicesn.mbi.ucla.edu/SAVES/>) server was used to observe amino acid distributions within studied protein models.

2.5. Active site prediction and mobility analysis

Active sites identification is a crucial step in drug discovery which evaluates the size of an active site, the number and properties of sub-sites and details of binding interaction [95]. CASTp (computed atlas of surface topography of proteins) server predicted the active sites in the refined models of three MTA proteins [96]. iMODs server represents the collective motion of proteins by evaluating the normal modes (NMA) in internal coordinates [97]. It predicted the extent as well as direction of the inherent motions of studied proteins. The deformability, eigen values and covariance-matrix were also analyzed.

2.6. Screening of plant metabolites against MTA proteins and analysis of drug surface hotspots

Molecular Docking is a beneficial tool to perform virtual screening on various compounds and to infer how the ligands inhibit their targets [98]. The binding affinities of 50 plant metabolites with 3 MTA proteins were determined using PatchDock server [99]. In this study, Metarrestin (Pubchem CID: 50985821) was used as positive controls for their inhibitory features against MTA proteins. The docked complexes were refined via FireDock refinement tool [100]. Visualization of ligand binding complexes was performed by Discovery Studio v3.1 [101] and PyMOL v2.0 software [102].

2.7. Molecular dynamics study

Stability of the docked complex was predicted by molecular dynamics study. The structural dynamics of the studied proteins were assessed using iMOD server for its quick and effective measurements than other molecular dynamics (MD) simulations tools [103; 104]. The structural communications fingerprints in the biomolecules were measured through exploring global metapath and path distribution via WebPSN server [105]. Moreover, the protein dynamics as like the protein contact maps for simulation trajectory, fluctuation plots were analyzed by CABS-flex 2.0 server, CABS-flex is more suited to detect non-obvious dynamic fluctuations within, for example, the biologically important, well-defined secondary structural elements [106].

2.8. Drug profile analysis of top metabolites

Absorption, distribution, metabolism, and excretion (ADME) properties are significant pharmacological features to facilitate drug development processes for safe and effective therapeutics production [107]. SwissADME server was used to evaluate ADME properties of top plant metabolites [108]. To assess the Blood-brain barrier (BBB) in the studied compounds, BOILED-Egg model was applied [109]. Moreover, pkCSM, an online tool was prioritizing to evaluate the relative toxicity of top metabolites [110, 111].

2.9. Prediction of drug targets and available drug molecules from drugbank

SwissTargetPrediction tool was used to assume the macromolecular drug targets of top metabolites [112]. Furthermore, SwissSimilarity web tool was employed to identify already approved drug molecules with similar structure from DrugBank [113]. The server performed ligand-based virtual screening of several libraries of small molecules to trace approved, experimental and commercially available drugs from DrugBank [113].

3. Results

3.1. Retrieval of metastasis-associated proteins and plant metabolites

UniProt entry Q13330 (715 amino acids), O94776 (668 amino acids) and Q9BTC8 (594 amino acids) corresponding to MTA1, MTA2 and MTA3 respectively, were retrieved and cross-checked with NCBI protein database accession numbers (i.e. NP_004680.2, NP_004730.2 and NP_001317371.1 respectively) (Table 1). PubChem ID, molecular weight, formula, source, function and others properties of retrieved 50 metabolites were listed in Table 2.

3.2. Analysis of physicochemical properties and sub-cellular localization

The molecular weight of the metastasis-associated proteins ranged from 67.5 to 80.8 kDa. The isoelectric points were predicted between 8.80 and 9.70, suggesting that the proteins are basic in nature. Moreover, aliphatic index around 75 revealed the proteins as thermo-stable. The negative GRAVY values indicated that the proteins will have a good interaction with water (Table 3). The localization of the MTA proteins (i.e. MTA1, MTA2, MTA3) were predicted as nuclear protein.

3.3. Secondary structure prediction and functional analysis

Results showed that MTA1 had 62.9% (450 residues) helix, 30.8% (220 residues) sheet and 15% (107 residues) turn, while MTA2 showed to have 68.9% (460 residues) helix, 37.0% (247 residues) sheet and 13.6% (91 residues) turn regions. Similarly, MTA3 exhibited 63.3% (376 residues) helix, 44.4% (264 residues) sheet and 15.5% (92 residues) turns. Higher numbers of α -helices are suggesting these proteins as thermostable (Figure 1) [114]. All of the studied proteins comprised one Homeodomain-like superfamily and one Myb/SANT domain family (Figure 2). Protein annotation resource NCBI-CDD revealed that these MTA proteins have five domains, namely Bromo Adjacent Homology domain (BAH MTA), MTA R1 domain, Myb-Like DNA-Binding Domain (SANT MTA3 like domain), zinc finger binding to DNA consensus sequence [AT]GATA[AG] (ZnF_GATA) and the ELM2 (Egl-27 and MTA1 homology 2) domain (Figure 2). Only MTA2 had an additional domain named PHA03247 super family that is large tegument protein UL36. MotifFinder predicted six motifs, MTA_R1, BAH, ELM2, GATA, Myb_DNA-binding and Myb_DNA-bind_7 for each protein. Again, MTA2 showed an extra motif named Cytochrome C₃ (Figure 2B).

3.4. Tertiary structure prediction, refinement and validation

I-TASSER server performed three dimensional homology modeling and predicted five models for each protein. The best models were identified based on C-Score (Figure 3-5A), which showed overall quality factors 79.914(MTA1), 80.793(MTA2) and 85.665 (MTA3) at 0.01 and 0.05 level of significance (Figure 3-5B). The results of Ramachandran plot analysis revealed 87.2% residues in favored, 9% residues in allowed and 3.8% residues in the outlier region for MTA1. The refined models of MTA2 and MTA3 showed 88.4% and 91.2% residues in the favored region, while only 1.8% and 1.9% residues were in the outlier region, respectively (Figure 3-5C). Besides, the amino acid distributions of the refined models were revealed by comparing expected and observed structure through SAVES server (Figure 3-5D).

3.5. Active site prediction and mobility analysis

CASTp server revealed 135, 138 and 93 active sites for refined models of MTA1, MTA2 and MTA3 (Supplementary file 1). The best pockets showed an area and volume of 1318.734 (SA) and 557.492 (SA) for MTA1; 901.007 (SA) and 1563.224(SA) for MTA2; 4094.143 (SA) and 3963.371 (SA) for MTA3 protein (Figure 6). Stability of the modeled structures was determined in terms of deformability, eigenvalue and covariance matrix. The main-chain deformability of the MTA proteins was negligible as indicated by hinges in the chain (Figure 3-5E). The higher eigenvalues of MTA1 ($8.456619e^{-08}$), MTA2 ($8.839058e^{-05}$) and MTA3 ($1.015865e^{-05}$) are representative of higher energy which is required to deform the protein structures (Figure 3-5G). The elastic network models as shown in Figure 3-5F; defined the pairs of atoms connected by springs, where dots are colored according to the degree of stiffness.

3.6. Screening of plant metabolites against MTA proteins and analysis of drug surface hotspots

The MTA proteins (macromolecules) and plant metabolites (ligands) were used for molecular docking to assess the affinity between the ligands and macromolecules. Top metabolites were ranked according to the global binding energy (Supplementary file 2). Notably, isoflavone, gingerol, citronellal and asiatic acid showed higher binding affinity with each of the three

proteins and featured in the top list (Table 5). Isoflavone showed maximum binding interaction with MTA2 (-54.70 kcal/mol) and MTA3 (-69.20kcal/mol) (Figure 7B and 7C; Table 5). Gingerol also experienced minimum binding energy with MTA1 (-51.23kcal/mol), MTA2 (-52.71 kcal/mol) and MTA3 (-48.02 kcal/mol) protein (Figure 7A, Table 5). The ligand binding interactions and structural conformations of each protein were investigated to unravel the drug surface hotspots. Results revealed that the regions from 433 to 498 and 629 to 633 were crucial binding sites for MTA1 protein, where Pro629, Lys631, Val632, Arg633 positions were most dominant. Again, residues of 333-397 and 616-624 regions were identified as top surface hotspot for MTA 2. Moreover, two residues i.e. Lys618 and Ala619 were involved to form the docked complexes in maximum cases. The ligands showed maximum binding affinity for the region of 425 to 458 amino acid sequences in case of MTA3 protein.

3.7. Molecular dynamics study

The iMODS server conducted such an analysis taking into account the complex molecule's internal coordinates, the B-factor values obtained from NMA are equal to RMS (Figure 10). The interaction of MTA1 and Gingerol revealed the total number of nodes involved in the recurrent links was 102. The highest average correlation between each node was 1.57067 with an average path correlation of 1.57067 and the total hubs determined were 90, while the average percentage of hub nodes present in the global pool was 45.09% (Figure 10A). Additionally, the average of the interaction strength among the links present in the global pool was designated by path force 5.82366. The meta path generated from the interactions of isoflavone with MTA2 and MTA3 revealed 116,84 and 115,83 nodes respectively (Figure 10B and Figure 10C). Maximum path correlation was found 1 for both cases with an average path correlation 0.9686689 and 0.974525, respectively for MTA1 and MTA2. The average path force was 6.7 in MTA1 and 7.15 in case of MTA2. The protein dynamics analysis of complexes provided by the CABS-flex 2.0 server insights the flexible and rigid portions of the complexes. The MTA1-gingerol, MTA2-Isoflavone and MTA3-isoflavone complexes had lesser fluctuations in top integrated best 10 models (Figure 11). The root mean square fluctuation plot insights the MTA1-Gingerol, MTA2-isoflavone and MTA3-isoflavone complex's fluctuation ranged 0-16 Å, 0-7 Å, 0-5.5 Å respectively (Figure 11).

3.8. Drug profile analysis of top metabolites

Several ADME properties including physicochemical parameters, pharmacokinetics, lipophilicity, water solubility and medicinal chemistry of top metabolites were demonstrated to evaluate their druggability potential (Figure 8). In this study, each drug candidate showed high GI absorption. Blood-brain barrier permeation computed by BOILED-Egg model revealed no BBB permeation for isoflavone, gingerol and asiatic acid. Besides, analysis of inhibition effects with different CYP isoforms (e.g. CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4) confirmed that almost all candidates do not interact with cytochromes P450 isoforms. The metabolites showed bioavailability score of 0.5 and water solubility at moderate levels (Table 6).

3.9. Toxicity pattern analysis of top metabolites

The relative toxicity (i.e AMES toxicity, oral rat toxicity, hepatotoxicity, skin sensitization, *T. pyriformis* toxicity, minnow toxicity) of top metabolites were predicted via pkCSM server. The results revealed negative outcomes in AMES test for isoflavone, gingerol, and asiatic acid indicating no risk of mutagenic or carcinogenic toxicity. The top drug candidates did not interact with hERGI (human ether-a-go-go related gene I) and hERG II, confirming that they are not hERG inhibitors. Moreover, top candidates revealed negative results for skin sensitization and hepatotoxicity. Minnow Toxicity values of all metabolites were greater than -0.3 log mM indicating them as non-toxic. Besides, maximum tolerated dose, oral rat acute toxicity (LD50), oral rat chronic toxicity (LOAEL) and *T. pyriformis* toxicity did not show any undesirable effects by the top drug candidates that could reduce their drug-likeness properties (Table 7).

3.10. Prediction of drug targets and available drug molecules from drugbank

Most of the target classes covered by the top drug candidates belonged to enzymes (e.g. oxidoreductase, phosphatase, lyase), nuclear receptors and secreted proteins (Figure 9, Table 8). SwissSimilarity prediction revealed that several approved drugs i.e. Tramadol, Estradiol, Nabumetone could be an alternative to Gingerol to block MTA proteins (Table 9). Moreover, Ethanolamine Oleate, Dihomo-gamma-linolenic acid (DGLA), 4-Androstenedione and some

other synthetic analogs may be potent drugs which showed significant structural similarity with Citronella (Table 9).

4. Discussion

Despite extensive research and occasional successes, most of the cancer treatments are still a long way from reality [115]. Though treatments are available in some instances, not everyone can afford their prescriptions (one in five) and pay for treatments (one in four) [116]. Products of MTA gene family are involved and accelerate the migration, invasion, and survival of immortal cells in human. In this study, attempts were taken to reveal novel therapeutic option to prevent metastasis and cancer progression at early stages. Limited progress has been made so far in the treatment of cancer metastasis [117] and to the best of our knowledge similar computational strategies have not been yet explored to identify potential inhibitors of MTA gene products. The super-family, conserved domains and motifs of 3 MTA proteins i.e. MTA 1, MTA 2, MTA were analyzed to determine their functions. To date no crystal structure was determined for the MTA family proteins. Hence, homology modeling was performed for protein structure prediction from the available sequence data [118]. The 3D modeled structures were further studied extensively and validated through Ramachandran Plot and quality factor analysis (Figure 3-5). Moreover, ascertainment of stability can be done by comparing proteins essential dynamics to their normal modes [119, 120]. The refined models were significantly stable and showed minimum deformability at molecular level.

Virtual screening and de novo *drug* designing approaches are effective tools to identify novel hit molecules with desired biological activity [121, 122]. Analyzing the interaction between macromolecules and small ligands is an effective way to simplify the path of modern drug discovery [75], which also minimize the time and cost for drug development process [123]. In the next step, we performed structure based virtual screening for *in silico* evaluation of some plant based bioactive compounds as potent MTA inhibitors. Results showed that isoflavone, gingerol, citronellal and asiatic acid were the top hit molecules regarding minimum global binding energy. Asiatic acid, a triterpenoid derivative from *Centella asiatica*, was reported to have antioxidative, anti-angiogenic, anti-inflammatory, and neuro-protective activities [124, 125]. Both *in vitro* and *in vivo* studies confirmed the inhibition of lung and liver cancer by asiatic

acid [126, 127]. Citronella essential oils are often used as natural antimicrobials and showed to prevent the growth of harmful airborne bacteria [128, 129]. A recent study also revealed the potential use of citronella oil as chemotherapeutic agents against cancer [130]. Protective roles of plant flavonoids against cancer and heart disease were reported long ago [131]. Isoflavonoids were likely to be protective against a number of tumors and breast cancer [132]. In 2018, de Lima and colleagues reported the therapeutic potential of gingerol (*Zingiber officinale* extract) as anti cancer agent [133]. Previously gingerol showed to suppress colon cancer by targeting leukotriene A4 hydrolase [134]. Gingerol inhibits tumor growth and metastasis in human breast cells [135].

The drug surface hotspots and ligand binding interactions of the studied MTA proteins were unraveled (Table 5). Results showed that isoflavon and citronella occupied the BAH domains of MTA 1 and MTA 3 protein, respectively. In case of Asiatic acid, most of the ligand binding residues blocked the MTA-R1 domains of MTA 1 and MTA 2 protein (Table 5, Figure 7). The top drug candidates also inhibited the crucial binding sites of GATA and Myb-DNA binding domains of the MTA proteins. Most of the enzyme class (e.g. oxidoreductase, phosphatase, lyase) and nuclear receptors were identified as main targets by the top drug candidates (Table 8) carbonic anhydrases (CAs) have been shown to be important mediators of tumor cell pH by modulating the bicarbonate and proton concentrations for cell survival and proliferation [136]. This has led the researchers to inhibit specific CA isoforms, as an anti-cancer therapeutic strategy. Moreover, current evidence suggests that ECE-1c contributes to cancer aggressiveness and plays a putative role as a key regulator of cancer progression [137]. Alcohol/Aldehyde dehydrogenase (ADH) is used by cancer cells for energy, while the increase in total ADH in sera was positively correlated with renal *cancer* [138, 139]. Another enzyme *γ-secretase* is thought to play a significant *role* in tumorigenesis and pancreatic *cancer* [140]. The result suggests that all these enzymes can be specifically targeted by top drug candidates. Moreover, different nuclear receptors [141, 142], estrogen receptor beta (ERβ) [143], Dopamine D2 receptor [144], Progesteron receptor [145] are actively involved in metastasis and cancer progression. These receptors may also serve as effective pharmacological target by top metabolites (Table 5).

Optimization of ADME profiles is crucial for the clinical and commercial successes of drugs [146]. No side-effect was reported in some randomized, placebo-controlled trials of isoflavone and citronella essential oil [147, 148]. Therapeutic uses of gingerol and asiatic acid are also considered as safe and were supported by some pharmacokinetic and preclinical studies [149, 150]. In the present study, the ADME analysis did not find any undesirable consequences by the top drug candidates. However, cautions should be taken for the repurposed use of these drugs to avoid any adverse effects. The molecular dynamics studies have grown into a sophistication that enables macromolecular structural function relationships to be fully understood [151]. The deformability analysis of modelled proteins revealed that the distortions were lesser atomic distortion and also the higher eigenvalues of MTA1 ($8.456619e^{-08}$), MTA2 ($8.839058e^{-05}$) and MTA3 ($1.015865e^{-05}$) are representative of higher energy which is required to deform the protein structures confirms the stability of modeled structures. Moreover, the docked complex B factor analysis revealed the lesser atomic distortions in the MTA1-gingerol and MTA2 -isoflavone docked complex but a bit in MTA3-isoflavone complex (Figure 10). The lesser atomic distortions also confirmed the stability of the complexes. The metapathway and hubs analysis shows interaction strength and cross-correlation of atomic motions of docked complex which implies to be a strong recurrent links between them (Figure 10). The minor fluctuations were observed in the RMSF plot, reflecting the uninterrupted interaction between the isoflavone and the MTA2, MTA3. Unlikely, higher fluctuations ranging over 10 Å, were observed in the RMSF plot, thus confirming a bit flexibility of the docked complex of gingerol and MTA1 (Figure 11).

We further performed ligand based virtual screening to identify similar drug molecules using a large collection of 3,76,342 compounds from DrugBank which are experimentally active on different macromolecular targets [112]. Results revealed that several synthetic analogs of gingerol (i.e. Tramadol, Estradiol, Nabumetone) may efficiently block the MTA proteins. Tramadol is a synthetic opioid which can be administered orally, subcutaneously, intravenously, intramuscularly, rectally and spinally [152]. It has been found to be a useful drug in patients with cancer pain (both with nociceptive and neuropathic characteristics) [153]. Estradiol is a major regulator of growth for the subset of breast cancers that express the estrogen receptor. Breast cancer cell lines that undergo long-term estrogen deprivation can be growth-inhibited by estradiol. High dose estrogen can be used to induce caspase-mediated death [154]. Nabumetone,

on the other hand, can inhibit cyclooxygenase-COX enzyme and are thought to be tumor suppressor [155]. COX-2 and PG overexpression in chronic inflammation suggest that PGs produced by COX-2 catalysis can provide nutrition for tumor survival and proliferation [156]. Thus, Nabumetone can be used to inhibit COX and prostaglandin level which is a major factor for tumor formation. Results also suggest that Progesterone and Dihomo-gamma-linolenic acid (DGLA) may be an alternative choice to Citronella. Maintaining the balance of progesterone and unsaturated fatty acid have been found to exert clinical efficacy in arresting cancer cell and tumor growth [157, 158]. Another approved drug, Hydrocortisone showed high similarity with asiatic acid, which can be used for patients with advanced breast cancer. Though its mechanism of action is still unclear, a direct role in cell killing has been postulated for this glucocorticoid drug [159]. It is inevitable that computational target prediction provides valuable information for drug repurposing, understanding side effects and expanding the druggable genome [160-162]. Therefore, this study may pave the way of drug development against cancer metastasis in future.

5. Conclusion

The study suggests that isoflavone, gingerol, citronellal and asiatic acid could be potent MTA inhibitors to prevent cancer metastasis. Furthermore, several biologically active structural analogs from DrugBank i.e. Tramadol, Nabumetone, DGLA, Hydrocortisone may be effective and show potency to inhibit cancer progression in the early stage. However, the results are solely based on *in silico* investigations. Due to the encouraging results, we highly recommend further *in vitro* and *in vivo* trials using model animals for the experimental validation of the findings.

Conflict of interest

The authors declare that they have no conflict of interests.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

Authors would like to acknowledge the Department of Microbial Biotechnology of Sylhet Agricultural University for the technical support of this research

References

- [1] National Institutes of Health (US); Biological Sciences Curriculum Study. NIH Curriculum Supplement Series [Internet]. Bethesda (MD): National Institutes of Health (US); 2007. Understanding Emerging and Re-emerging Infectious Diseases. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK20370/>.
- [2] L. Lin, L. Yan, Y. Liu, F. Yuan, H. Li, J. Ni, Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study, *J Hematol Oncol.* 12 (2019) 96. <https://doi.org/10.1186/s13045-019-0783-9>
- [3] X. Ma, H. Yu, Cancer issue: global burden of cancer, *Yale J Biol Med.* 79 (2006) 85-94.
- [4] G. M. Cooper, *The Cell: A Molecular Approach*, 2nd ed., Sunderland (MA): Sinauer Associates, 2000. The Development and Causes of Cancer. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK9963/>.
- [5] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA Cancer J. Clin.* 68 (2018) 394-424. <https://doi.org/10.3322/caac.21492>.
- [6] T.N. Seyfried, *Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer*, John Wiley & Sons, Hoboken, 2012, pp. 432.
- [7] G.P. Gupta, J. Massague, Cancer metastasis: building a framework, *Cell.* 127 (2006) 679-695. <https://doi.org/10.1016/j.cell.2006.11.001>.
- [8] X. Guan, Cancer metastases: challenges and opportunities, *Acta Pharm. Sin. B.* 5 (2015) 402-418. <https://doi.org/10.1016/j.apsb.2015.07.005>.
- [9] M. Bacac, I. Stamenkovic, Metastatic cancer cell, *Annu. Rev. Pathol.* 3 (2008) 221-247. <https://doi.org/10.1146/annurev.pathmechdis.3.121806.151523>.

- [10] S. Balasenthil, A. E. Gururaj, A. H. Talukder, R. B. Yarmand, T. Arrington, B. J. Haas, J. C. Braisted, I. Kim, N. H. Lee, R. Kumar, Identification of Pax5 as a target of MTA1 in B-cell lymphomas, *Cancer Res.* 67 (2007) 7132-7138. <https://doi.org/10.1158/0008-5472>.
- [11] P. R. Molli, R. R. Singh, S. W. R. Kumar, MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene, *Oncogene.* 27 (2008) 1971-1980. <https://doi.org/10.1038/sj.onc.1210839>.
- [12] D. Q. Li, S. D. N. Reddy, S. B. Pakala, X. Wu, Y. Zhang, S.K. Rayala, R. Kumar, MTA1 coregulator regulates p53 stability and function, *J. Biol. Chem.* 284 (2009) 34545-34552. <https://doi.org/10.1074/jbc.M109.056499>.
- [13] L. Cong, S. B. Pakala, K. Ohshir, D. Q. Li, R. Kumar, SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function, *J. Biol. Chem.* 286 (2011) 43793-43808. <https://doi.org/10.1074/jbc.M111.267237>
- [14] A.E. Gururaj, R.R. Singh, S.K. Rayala, C. Holm, P.D. Hollander, H. Zhang, S. Balasenthil, A.H. Talukder, G. Landberg, R. Kumar, MTA1, a transcriptional activator of breast cancer amplified sequence 3, *Proc. Natl. Acad. Sci.* 103 (2006) 6670-6675. <https://doi.org/10.1073/pnas.0601989103>
- [15] H.J. Kang, M.H. Lee, H.L. Kang, S.H. Kim, J.R. Ahn, H. Na, T.Y. Na, Y.N. Kim, J.K. Seong, M.O. Lee, Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1, *Cancer Res.* 74 (2014) 1484-1494. <https://doi.org/10.1158/0008-5472>.
- [16] B. Zhang, H. Zhang, G. Shen, Metastasis-associated protein 2 (MTA2) promotes the metastasis of non-small-cell lung cancer through the inhibition of the cell adhesion molecule Ep-CAM and E-cadherin, *Jpn. J. Clin. Oncol.* 45 (2015) 755-766. <https://doi.org/10.1093/jjco/hyv062>.
- [17] N. Fujita, D. L. Jaye, M. Kajita, C. Geigerman, C. S. Moreno, P. A. Wade, MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer, *Cell*, 113 (2003) 207-219. [https://doi.org/10.1016/S0092-8674\(03\)00234-4](https://doi.org/10.1016/S0092-8674(03)00234-4).
- [18] N. Fujita, D. L. Jaye, C. Geigerman, A. Akyildiz, M. R. Mooney, J. M. Boss, P. A. Wade, MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation, *Cell*. 119 (2004) 75-86. <https://doi.org/10.1016/j.cell.2004.09.014>.

- [19] Y. Toh, S. Kuninaka, K. Endo, T. Oshiro, Y. Ikeda, H. Nakashima, H. Baba, S. Kohnoe, T. Okamura, G.L. Nicolson, K. Sugimachi, Molecular analysis of a candidate metastasis-associated gene, MTA1: Possible interaction with histone deacetylase 1, *J. Exp. Clin. Cancer Res.* 19 (2000) 105-11.
- [20] N.J. Bowen, N. Fujita, M. Kajita, P.A. Wade, Mi-2/NuRD: multiple complexes for many purposes, *Biochim. Biophys. Acta.* 1677 (2004) 52-57. <https://doi.org/10.1016/j.bbaexp.2003.10.010>
- [21] D.Q. Li, R. Kumar, Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer, *Advances in Cancer Research.* 127 (2015) 1–47. <https://doi.org/10.1016/bs.acr.2015.04.005>.
- [22] R. Kumar, A.E. Gururaj, Coregulators as Oncogenes and Tumor Suppressors, in: B.W. O'Malley, R. Kumar (Eds.), *Nuclear Receptor Coregulators and Human Diseases*, N.J. Hackensack, World Scientific, 2008, pp. 195–218.
- [23] Y. Xue, J. Wong, G.T. Moreno, M.K. Young, J. Côté, W. Wang, NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities, *Mol. Cell.* 2 (1998) 851–861. [https://doi.org/10.1016/S1097-2765\(00\)80299-3](https://doi.org/10.1016/S1097-2765(00)80299-3).
- [24] N. Sen, B. Gui, R. Kumar, Role of MTA1 in cancer progression and metastasis, *Cancer Metastasis Rev.* 33 (2014) 879–89. <https://doi.org/10.1007/s10555-014-9515-3>.
- [25] X.F. Liu, M.K. Bagchi, Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo, *J. Biol. Chem.* 279 (2004):15050–15058. <https://doi.org/10.1074/jbc.M311932200>
- [26] B. Manavathi, R. Kumar, Metastasis Tumor Antigens, an Emerging Family of Multifaceted Master Coregulators, *J. Biol. Chem.* 282 (2007) 1529-1533. <https://doi.org/10.1074/jbc.R600029200>
- [27] K.R. Covington, S.A.W. Fuqua, Role of MTA2 in human cancer, *Cancer Metastasis Rev.* 33 (2014) 921–928. <https://doi.org/10.1007/s10555-014-9518-0>.
- [28] Y. Cui, A. Niu, R. Pestell, R. Kumar, E.M. Curran, Y. Liu, S.A.W. Fuqua, Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells, *Mol. Endocrinol.* 20 (2006) 2020–2035. <https://doi.org/10.1210/me.2005-0063>.

- [29] A. Simpson, J. Uitto, U. Rodeck, M.G. Mahoney, Differential expression and subcellular distribution of the mouse metastasis-associated proteins Mta1 and Mta3, *Gene*. 273 (2001) 29–39. [https://doi.org/10.1016/S0378-1119\(01\)00563-7](https://doi.org/10.1016/S0378-1119(01)00563-7).
- [30] R.C. Potts, P. Zhang, A.L. Wurster, P. Precht, M.R. Mughal, W.H. Wood III, Y. Zhang, K. G. Becker, M. P. Mattson, M. J. Pazin, CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes, *PLoS One*. 6 (2011) e24515. <https://doi.org/10.1371/journal.pone.0024515>.
- [31] S. Koc, B.S. Isgor, Y.G. Isgor, N.S. Moghaddam, O. Yildirim, The potential medicinal value of plants from Asteraceae family with antioxidant defense enzymes as biological targets, *Pharm. Biol.* 53 (2015) 746-751. <https://doi.org/10.3109/13880209.2014.942788>.
- [32] X.J. Liang, C. Chen, Y. Zhao, P.C. Wang, Circumventing tumor resistance to chemotherapy by nanotechnology, in: J. Zhou (Eds), *Multi-Drug Resistance in Cancer, Methods in Molecular Biology (Methods and Protocols)*, Humana Press, 2010, pp. 467-488. https://doi.org/10.1007/978-1-60761-416-6_21.
- [33] P.M. Cheuka, G. Mayoka, P. Mutai, K. Chibale, The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases, *Molecules*. 22 (2016) 58. <https://doi.org/10.3390/molecules22010058>.
- [34] A. Karimi, M. Majlesi, M. Rafieian-Kopaei, Herbal versus synthetic drugs; beliefs and facts, *J. Nephroarmacol.* 4 (2015) 27-30.
- [35] G. El-Saber Batiha, A.M. Beshbishy, L.G. Wasef, Y.H. Elewa, A.A. Al-Sagan, M.E.A. ElHack, A.E. Taha, Y.M. Abd-Elhakim, H.P. Devkota, Chemical constituents and pharmacological activities of garlic (*allium sativum* L.): a review, *Nutrients*. 12 (2020) 872. <https://doi.org/10.3390/nu12030872>
- [36] J.C. Ozougwu, J.E. Eyo, Evaluation Of The Activity Of Zingiber Officinale (Ginger) Aqueous Extracts On Alloxan-Induced Diabetic Rats, *Pharmacologyonline*. 1 (2011) 258-269.
- [37] E. Mussard, A. Cesaro, E. Lespessailles, B. Legrain, S. Berteina-Raboin, H. Toumi, Andrographolide, a natural antioxidant: an update, *Antioxidants* 2019;8(12):571.
- [38] B. Salehi, A. Venditti, M. Sharifi-Rad, D. Kręgiel, J. Sharifi-Rad, A. Durazzo, M. Lucarini, A. Santini, E.B. Souto, E. Novellino, H. Antolak, The therapeutic potential of apigenin, *Int. J. Mol. Sci.* 20 (2019) 1305. <https://doi.org/10.3390/ijms20061305>.

- [39] T.F. Okujagu, S.O. Etaturvie, I. Eze, B. Jimoh, C. Nwokereke, C. Mbaaji, Z. Mohammed, Medicinal plants of Nigeria, north-west Nigeria, *Nigerian Journal of Natural Product & Medicine* 1 (2008) 32-34.
- [40] T. Odugbemi, *Outlines and pictures of medicinal plants from Nigeria*, University of Lagos Press, Lagos, 2006, pp. 283.
- [41] M.F. Nagoor Meeran, S.N. Goyal, K. Suchal, C. Sharma, C.R. Patil, S.K. Ojha, Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: a pentacyclic triterpenoid of therapeutic promise, *Front. Pharmacol.* 9 (2018) 892. <https://doi.org/10.3389/fphar.2018.00892>.
- [42] Z. Wang, F. Li, Y. Quan, J. Shen, Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF- κ B/COX-2/PPAR- γ activities, *Mol. Med. Rep.* 19 (2019) 5417–23. <https://doi.org/10.3892/mmr.2019.10198>.
- [43] M. Hayman, P.C.A. Kam, Capsaicin: a review of its pharmacology and clinical applications, *Curr. Anaesth Crit. Care.* 19 (2019) 338–343. <https://doi.org/10.1016/j.cacc.2008.07.003>.
- [44] S.A. Bhalerao, D.R. Verma, R.V. Gavankar, N.C. Teli, Y.Y. Rane, V.S. Didwana, A. Trikannad, Phytochemistry, pharmacological profile and therapeutic uses of piper betle linn.– an overview, *J. Pharmacogn Phytochem.* 1 (2013) 10–19.
- [45] P. Shaba, N.N. Pandey, O.P. Sharma, J.R. Rao, R.K. Singh, Anti-trypanosomal Activity of Piper Nigrum L (Black pepper) Against Trypanosoma Evansi, *J. Vet. Adv.* 4 (2012) 161-167.
- [46] P. Moongkarndi, N. Kosem, O. Luanratana, S. Jongsomboonkusol, N. Pongpan, Antiproliferative activity of Thai medicinal plant extracts on human breast adenocarcinoma cell line. *Fitoterapia.* 75 (2004) 375-377. <https://doi.org/10.1016/j.fitote.2004.01.010>.
- [47] J.D. Guzman, Natural cinnamic acids, synthetic derivatives and hybrids with antimicrobial activity, *Molecules.* 19 (2014) 19292-19349. <https://doi.org/10.3390/molecules191219292>.
- [48] G. Obho, Antioxidant and Antimicrobial Properties of Ethanolic Extract of Ocimum gratissimum Linn Leaves, *J. Pharmacol. Toxicol.* 1 (2006) 47-53.

- [49] D. Amic, D. Davidovic-Amic, D. Beslo, N. Trinajstic, Structure-Radical scavenging activity relationship of flavonoids. *Croatia Chem. Acta.* 76 (2003) 55-61.
- [50] O.C. Nwinyi, N.S. Chinedu, O.O. Ajani, C.O. Ikpo, K.O. Ogunniran, Antibacterial effect of extracts of *Ocimum gratissimum* and *Piper guineense* on *Escherichia coli* and *Staphylococcus aureus*, *Afr. J. Food Sci.* 3 (2009) 77– 81.
- [51] I.R. Iroha, E.S. Amadi, A.C. Nwuzo, F.N. Afiukwa, Evaluation of the Antibacterial Activity of Extracts of *Sida acuta* Against Clinical Isolates of *Staphylococcus aureus* Isolated from Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients, *Res. J. Pharmacol.* 3 (2009) 22-25.
- [52] A. Al-Samydai, N. Jaber, Pharmacological aspects of curcumin: review article, *Int. J. Pharm.* 5 (2018) 313–326.
- [53] I.O. Lawal, N.E. Uzokwe, A.B.I. Igboanugo, A.F. Adio, E.A. Awosan, J.O. Nwogwugwu, B. Faloye, B.P. Olatunji, A.A. Adesoga, Ethno medicinal information on collation and identification of some medicinal plants in Research Institutes of South-west Nigeria, *Afr. J. Pharm. Pharmacol.* 4 (2010) 001-007. <https://doi.org/10.5897/AJPP.9000135>.
- [54] S.M. Nejad, H. Ozgünes, N. Basaran, Pharmacological and toxicological properties of eugenol, *Turk. J. Pharm. Sci.* 14 (2017) 201–206. <https://doi.org/10.4274/tjps.62207>.
- [55] A. Farombi, O. Ogundipe, J.O. Moody, Antioxidant and Antinflammatory activities of *Mallotus oppositifolium* in Model Systems, *Afr. J. Med. Med. Sci.* 30 (2001) 213-215.
- [56] D.K. Patel, K. Patel, M. Gadewar, V. Tahilyani, Pharmacological and bioanalytical aspects of galangin-a concise report, *Asian Pac. J. Trop. Biomed.* 2 (2012) S449–S455. [https://doi.org/10.1016/S2221-1691\(12\)60205-6](https://doi.org/10.1016/S2221-1691(12)60205-6).
- [57] F. Abedi, B.M. Razavi, H.A. Hosseinzadeh, Review on gentisic acid as a plant derived phenolic acid and metabolite of aspirin: comprehensive pharmacology, toxicology, and some pharmaceutical aspects, *Phytother. Res.* 34 (2019) 729–741. <https://doi.org/10.1002/ptr.6573>.
- [58] G.R. Prabu, A. Gnanamani, S. Sadulla, Guaijaverin—a plant flavonoid as potential antiplaque agent against *Streptococcus mutans*, *J. Appl. Microbiol.* 101 (2006) 487–495. <https://doi.org/10.1111/j.1365-2672.2006.02912.x>.

- [59] M. Imran, B. Salehi, J. Sharifi-Rad, T.A. Gondal, F Saeed, A. Imran, M. Shahbaz, P.V. Tsouh Fokou, M. Umair Arshad, H. Khan, S.G. Guerreiro, N. Martins, L.M. Estevinho, Kaempferol: A Key Emphasis to Its Anticancer Potential, *Molecules*. 24 (2019) 2277. <https://doi.org/10.3390/molecules24122277>.
- [60] M. Lopez-Lazaro, Distribution and biological activities of the flavonoid Luteolin, *Med. Chem.* 9 (2009) 31–59. <https://doi.org/10.2174/138955709787001712>.
- [61] N.D. Onwukaeme, Medicinal plant of Nigeria Natural Medicine Development Agency Federal Ministry of Science and Technology, *Phytother. Res.* 9 (1995) 306-308.
- [62] A. Maalik, F.A. Khan, A. Mumtaz, A. Mehmood, S. Azhar, M. Atif, S. Karim, Y. Altaf, I. Tariq, Pharmacological applications of quercetin and its derivatives: a short review, *Trop. J. Pharmaceut. Res.* 13 (2014) 1561–1566. <https://doi.org/10.4314/tjpr.v13i9.26>,
- [63] J. Zhao, J. Wang, Y. Chen, R. Agarwal, Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotin protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent. *Carcinogenesis* 20 (1999) 1737-1745. <https://doi.org/10.1093/carcin/20.9.1737>.
- [64] E.E. Mgbeahuruike, T. Yrjonen, H. Vuorela, Y. Holm, Bioactive compounds from medicinal plants: focus on Piper species. *South Afr. J. Bot.* 112 (2017) 54–69. <https://doi.org/10.1016/j.sajb.2017.05.007>.
- [65] J.O. Kokwaro, Medicinal Plants of East Africa, Second ed., East African Literature Bureau, Nairobi, 1993.
- [66] A. Sofowora, Medicinal Plants and Traditional Medicine in Africa, Third ed., Spectrum Books, Ibadan, 2008.
- [67] R.L. Singh, P. Singh, A. Agarwal, Chemical constituents and bio-pharmacological activities of Swertia chirata: a review, *NPAIJ* 8 (2012) 238–247.
- [68] A. Ahmad, R.K. Mishra, A. Vyawahare, A. Kumar, M.U. Rehman, W. Qamar, A.Q. Khan, R. Khan, Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/ anticancer agent: chemistry and biological effects, *Saudi Pharmaceut. J* 27 (2019) 1113–1126. <https://doi.org/10.1016/j.jsps.2019.09.008>

- [69] I. Mourtzinis, S. Konteles, N. Kalogeropoulos, V.T. Karathanos, Thermal oxidation of vanillin affects its antioxidant and antimicrobial properties, *Food Chem.* 114 (2009) 791-797. <https://doi.org/10.1016/j.foodchem.2008.10.014>.
- [70] J.H. Kim, H.O. Lee, Y.J. Cho, J. Kim, J. Chun, J. Choi, Y. Lee, W.H. Jung, A vanillin derivative causes mitochondrial dysfunction and triggers oxidative stress in *Cryptococcus neoformans*, *PloS one*. 9 (2014) e89122. <https://doi.org/10.1371/journal.pone.0089122>.
- [71] H.J. Barrales-Cureno, Pharmacological applications and in vitro biotechnological production of anticancer alkaloids of *Catharanthus roseus*, *Biotechnol. Appl.* 32 (2015) 1101–1110.
- [72] M. He, J.W. Min, W.L. Kong, X.H. He, J.X. Li, B.W. Peng, A review on the pharmacological effects of vitexin and isovitexin, *Fitoterapia*. 115 (2016) 74–85. <https://doi.org/10.1016/j.fitote.2016.09.011>
- [73] K. Patel, R.B. Singh, D.K. Patel, Pharmacological and analytical aspects of withaferin A: a concise report of current scientific literature, *Asian Pac. J. Reprod.* 2 (2013) 238–243. [https://doi.org/10.1016/S2305-0500\(13\)60154-2](https://doi.org/10.1016/S2305-0500(13)60154-2).
- [74] Y. Johji, M. Michihiko, H.Q. Rong, M. Hisashi, F. Hajime, The anti-ulcer effect in rats of ginger constituents, *J. Ethnopharmacol.* 23 (1988) 299–304. [https://doi.org/10.1016/0378-8741\(88\)90009-8](https://doi.org/10.1016/0378-8741(88)90009-8)
- [75] D.B. Kitchen, H. Decornez, J.R. Furr, J. Bajorath, Docking and scoring in virtual screening for drug discovery: methods and applications, *Nat. Rev. Drug. Discov.* 3(2004) 935-949. <https://doi.org/10.1038/nrd1549>.
- [76] B.K. Shoichet, Virtual screening of chemical libraries, *Nature*. 432 (2004) 862-865. <https://doi.org/10.1038/nature03197>.
- [77] S.Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B. A.Shoemaker, J.Wang, PubChem substance and compound databases, *Nucleic Acids Res.* 44 (2016) D1202-D1213. <https://doi.org/10.1093/nar/gkv951>.
- [78] N. M. O'Boyle, M.Banck, C.A.James, C.Morley, T.Vandermeersch, G. R.Hutchison, Open Babel: An open chemical toolbox, *J. cheminformatics.* 3 (2011) 33. <https://doi.org/10.1186/1758-2946-3-33>.

- [79] K.F. Azim, S.R. Ahmed, A. Banik, M.M.R. Khan, A. Deb, S.R.Somana, Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach, *Inform. Med. Unlocked*. 20 (2020) 100367. <https://doi.org/10.1016/j.imu.2020.100367>.
- [80] E. Gasteiger, C. Hoogland, A. Gattiker, M.R. Wilkins, R.D. Appel, A. Bairoch, Protein identification and analysis tools on the ExPASy server, In *The proteomics protocols handbook*, Humana press, 2005, pp. 571-607.
- [81] C.S. Yu, C.J. Lin, J.K. Hwang, Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. *Protein sci.* 13 (2004) 1402-1406. <https://doi.org/10.1110/ps.03479604>.
- [82] B.R. King, C. Guda, ngLOC: an n-gram-based Bayesian method for estimating the subcellular proteomes of eukaryotes, *Genome boil.* 8 (2007) R68. <https://doi.org/10.1186/gb-2007-8-5-r68>.
- [83] D.W. Buchan, D.T. Jones, The PSIPRED protein analysis workbench: 20 years on, *Nucleic acids res.* 47 (2019) W402-W407. <https://doi.org/10.1093/nar/gkz297>.
- [84] G.S. Brandt, Secondary Structure, in: R.D. Wells, J.S. Bond, J. Klinman, B.S.S. Masters (Eds.), *Molecular Life Sciences*, Springer, New York, NY, 2018.
- [85] P.Y. Chou, G.D. Fasman, Prediction of protein conformation. *Biochem.* 13 (1974) 222-245. <https://doi.org/10.1021/bi00699a002>.
- [86] L.J. McGuffin, K. Bryson, D.T. Jones, The PSIPRED protein structure prediction server, *Bioinformatics.* 16 (2000) 404–405. <https://doi.org/10.1093/bioinformatics/16.4.404>.
- [87] J. Gough, K. Karplus, R. Hughey, C. Chothia, Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure, *J. mol. Biol.* 313 (2001) 903-919. <https://doi.org/10.1006/jmbi.2001.5080>.
- [88] A.P. Pandurangan, J. Stahlhacke, M.E. Oates, B. Smithers, J. Gough, The SUPERFAMILY 2.0 database: a significant proteome update and a new webserver. *Nucleic acids res.* 47 (2019) D490-D494. <https://doi.org/10.1093/nar/gky1130>.
- [89] A. Marchler-Bauer, M.K. Derbyshire, N.R. Gonzales, S. Lu, F. Chitsaz, L.Y. Geer, R.C. Geer, J. He, M. Gwadz, D.I. Hurwitz, C.J. Lanczycki, F. Lu, G.H. Marchler, J.S. Song,

- N. Thanki, Z. Wang, R.A. Yamashita, D. Zhang, C. Zheng, S.H. Bryant, CDD: NCBI's conserved domain database, *Nucleic acids res.* 43 (2015) D222-D226. <https://doi.org/10.1093/nar/gku1221>.
- [90] M. Kanehisa, S. Goto, S. Kawashima, A. Nakaya, The KEGG databases at GenomeNet. *Nucleic acids res.* 30 (2002) 42-46.
- [91] 91. J. Yang, R. Yan, A. Roy, D. Xu, J. Poisson, Y. Zhang, () The I-TASSER Suite: protein structure and function prediction. *Nat. Methods.* 12 (2015) 7-8. <https://doi.org/10.1038/nmeth.3213>.
- [92] J. Ko, H. Park, L. Heo, C. Seok, GalaxyWEB server for protein structure prediction and refinement, *Nucleic acids res.* 40 (2012) W294-W297. <https://doi.org/10.1093/nar/gks493>.
- [93] M.W. MacArthur, R.A. Laskowski, J.M. Thornton, 1994 Knowledge-based validation of protein structure coordinates derived by X-ray crystallography and NMR spectroscopy, *Curr. Opin. Struct. Biol.* 4 (1994) 731-737. [https://doi.org/10.1016/S0959-440X\(94\)90172-4](https://doi.org/10.1016/S0959-440X(94)90172-4).
- [94] S.C. Lovell, I.W. Davis, W.B. Arendall III, P.I.W. de Bakker, J.M. Word, M.G. Prisant, J.S. Richardson, D.C. Richardson, Structure validation by Ca geometry: F, C and Cb deviation, *Proteins.* 50 (2003) 437-450. <https://doi.org/10.1002/prot.10286>.
- [95] I. Schechter, Mapping of the active site of proteases in the 1960s and rational design of inhibitors/drugs in the 1990s, *Current Protein and Peptide Science* 6 (2005) 501-512. <https://doi.org/10.2174/138920305774933286>.
- [96] W. Tian, C. Chen, X. Lei, J. Zhao, J. Liang, CASTp 3.0: computed atlas of surface topography of proteins, *Nucleic acids res.* 46 (2018) W363-W367. <https://doi.org/10.1093/nar/gky473>.
- [97] J.R. Lopez-Blanco, J.I. Aliaga, E.S. Quintana-Orti, P. Chacon, iMODS: internal coordinates normal mode analysis server, *Nucleic Acids Res.* 42 (2014) W271–W276.
- [98] G.M. Morris, M. Lim-Wilby, Molecular docking, in: Kukol A. (Eds.), *Molecular Modeling of Proteins Methods, Methods Molecular Biology™*, Humana Press, 2008, pp. 365–382.

- [99] D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, H.J. Wolfson, PatchDock and SymmDock: servers for rigid and symmetric docking, *Nucleic acids res.* 33 (2005) W363-367. <https://doi.org/10.1093/nar/gki481>.
- [100] E. Mashiach, D.Schneidman-Duhovny, N.Andrusier, R.Nussinov, H. J.Wolfson, FireDock: a web server for fast interaction refinement in molecular docking, *Nucleic Acids Res.* 36 (2008) W229-W232. <https://doi.org/10.1093/nar/gkn186>.
- [101] Q.Wang, J.He, D.Wu, J.Wang, J.Yan, H.Li, Interaction of α -cyperone with human serum albumin: Determination of the binding site by using Discovery Studio and via spectroscopic methods, *J. Lumin.* 164 (2015) 81-85. <https://doi.org/10.1016/j.jlumin.2015.03.025>.
- [102] W.L. DeLano, Pymol: An open-source molecular graphics tool, *CCP4 Newsletter on protein crystallography*, 40 (2002) 82-92.
- [103] F.M. Awan, A. Obaid, A. Ikram, H.A. Janjua, Mutation-structure function relationship based integrated strategy reveals the potential impact of deleterious missense mutations in autophagy related proteins on hepatocellular carcinoma (HCC): a comprehensive informatics approach, *Int. J. Mol. Sci.* 18 (2017) 139. <https://doi.org/10.3390/ijms18010139>.
- [104] P.K. Prabhakar, A. Srivastava, K.K. Rao, P.V. Balaji, Monomerization alters the dynamics of the lid region in campylobacter jejuniCstII: an MD simulation study, *J. Biomol. Struct. Dyn.* 34 (2016) 778–779. <https://doi.org/10.1080/07391102.2015.1054430>.
- [105] A. Felling, M. Seeber, F. Fanelli, webPSN v2. 0: a webserver to infer fingerprints of structural communication in biomacromolecules. *Nucleic Acids Res.* 48 (2020) W94–W103. <https://doi.org/10.1093/nar/gkaa397>
- [106] A. Kuriata, A.M. Gierut, T. Oleniecki, M.P. Ciemny, A. Kolinski, M. Kurcinski, S. Kmiecik, CABS-flex 2.0: a web server for fast simulations of flexibility of protein structures, *Nucleic acids res.* 46 (2018) W338-W343.
- [107] J. Tibbitts, D. Canter, R. Graff, A. Smith, L.A. Khawli, Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. *MAbs.* 8 (2016) 229–245. <https://doi.org/10.1080/19420862.2015.1115937>.

- [108] A. Daina, O. Michielin, V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, *Sci. Rep.* 7 (2017) 42717. <https://doi.org/10.1038/srep42717>.
- [109] A. Daina, V. Zoete, A BOILED-Egg to Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules, *Chem. Med. Chem.* 11 (2016) 1117–1121. <https://doi.org/10.1002/cmdc.201600182>.
- [110] D.E. Pires, T.L. Blundell, D.B. Ascher, pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures, *Journal of Medicinal Chemistry* 58 (2015) 4066–4072. <https://doi.org/10.1021/acs.jmedchem.5b00104>.
- [111] M.R. Rahman, A. Banik, I.M. Chowdhury, E.H. Sajib, S. Sarkar, Virtual Screening of Some Antivirals That Can Be Repurposed As Potential Effective Drugs against SARS-CoV-2, 2020.. <https://doi.org/10.26434/chemrxiv.12923684.v1>.
- [112] A. Daina, O. Michielin and V. Zoete, SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules, *Nucleic Acids Res.* 47 (2019) W357-W364. <https://doi.org/10.1093/nar/gkz382>.
- [113] V. Zoete, A. Daina, C. Bovigny and O. Michielin, SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening, *J. Chem. Inf. Model.* 56 (2016) 1399-1404. <https://doi.org/10.1021/acs.jcim.6b00174>.
- [114] K. Pramanik, T. Soren, S. Mitra, T. K. Maiti, (2017). In silico structural and functional analysis of Mesorhizobium ACC deaminase. *Comput. Biol. Chem.* 68 (2017) 12-21. <https://doi.org/10.1016/j.compbiolchem.2017.02.005>.
- [115] S. Chakraborty, T. Rahman, The difficulties in cancer treatment, *ecancermedicalscience.* 6 (2012) <https://doi.org/10.3332/ecancer.2012.ed16>.
- [116] T.G. Knight, A.M. Deal, S.B. Dusetzina, H.B. Muss, S.K. Choi, J.T. Bensen, G.R. Williams, Financial toxicity in adults with cancer: adverse outcomes and noncompliance. *J. Oncol. Pract.* 14 (2018) e665-73.
- [117] X. Guan, Cancer metastases: challenges and opportunities. *Acta Pharm. Sin. B.* 5 (2015) 402-418. <https://doi.org/10.1016/j.apsb.2015.07.005>.

- [118] C.N. Cavasotto, S.S. Phatak, Homology modeling in drug discovery: current trends and applications. *Drug Discov. Today*.14 (2009) 676–683. <https://doi.org/10.1016/j.drudis.2009.04.006>.
- [119] D.M.F. Aalten, B.L. Groot, J.B.C. Findlay, H.J.C. Berendsen, A. Amadei, A Comparison of Techniques for Calculating Protein Essential Dynamics, *J. Comput. Chem.* 18 (1997) 169-181. [https://doi.org/10.1002/\(SICI\)1096-987X\(19970130\)18](https://doi.org/10.1002/(SICI)1096-987X(19970130)18).
- [120] K. Wuthrich, G. Wagner, R. Rene, B. Werner, Correlations between internal mobility and stability of globular proteins, *Biophys. J.* 32 (1980) 549-560. [https://doi.org/10.1016/S0006-3495\(80\)84989-7](https://doi.org/10.1016/S0006-3495(80)84989-7).
- [121] E. Lionta, G. Spyrou, D.K. Vassilatis, Z. Cournia, Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr. Top. Med. Chem.* 14(2014) 1923-1938.
- [122] K.H. Barakat, J.Y. Mane, J.A. Tuszynski, Virtual Screening: An Overview on Methods and Applications, in: *Handbook of Research on Computational and Systems Biology, Interdisciplinary Applications*, IGI Global, 2011, pp. 28-60.
- [123] E.H. Maia, L.C. Assis, T.A. de Oliveira, A.M. da Silva, A.G. Taranto, Structure-based virtual screening: from classical to artificial intelligence, *Front. Chem.* 8 (2020). <https://doi.org/10.3389/fchem.2020.00343>.
- [124] R.G. Krishnamurthy, M. Senut, D. Zemke, J. Min, M.B. Frenkel, E.J. Greenberg, S.W. Yu, N. Ahn, J. Goudreau, M. Kassab, K.S. Panickar. Asiatic Acid, a Pentacyclic Triterpene From *Centella asiatica*, Is Neuroprotective in a Mouse Model of Focal Cerebral Ischemia. *J. Neuroscience Res.* 87 (2009) 2541–2550. <https://doi.org/10.1002/jnr.22071>.
- [125] C.V. Kavitha, C. Agarwal, R. Agarwal, G. Deep, Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models, *PloS one*. 6 (2011) e22745. <https://doi.org/10.1371/journal.pone.0022745>.
- [126] T. Wu, J. Geng, W. Guo, J. Gao, X. Zhu, Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria, *Acta Pharm. Sin. B.* 7 (2017) 65-72. <https://doi.org/10.1016/j.apsb.2016.04.003>.
- [127] C. Sakonsinsiri, W. Kaewlert, N. Armartmuntree, R. Thanan, P. Pakdeechote, Anti-cancer activity of asiatic acid against human cholangiocarcinoma cells through inhibition of proliferation and induction of apoptosis, *Cell. Mol. Biol.* 64 (2018):28-33.

- [128] S. Sinha, D. Biswas, A. Mukherjee, Antigenotoxic and antioxidant activities of palmarosa and citronella essential oils, *J. Ethnopharmacol.* 137 (2011) 1521-1527. <https://doi.org/10.1016/j.jep.2011.08.046>.
- [129] L.D. Almeida, J.F. Paula, R.V. Almeida, D.W. Williams, J. Hebling, Y.W. Cavalcanti Efficacy of citronella and cinnamon essential oils on *Candida albicans* biofilms. *Acta Odontol. Scand.* 74 (2016) 393-398. <https://doi.org/10.3109/00016357.2016.1166261>.
- [130] G. Widiyarti, M. Megawati, M. Hanafi, The Potential use of Geraniol Esters from Citronella Oil as Anticancer Agents, *Orient. J. Chem.* 35 (2019) 987. <http://dx.doi.org/10.13005/ojc/350310>.
- [131] 131. H. Wiseman, The therapeutic potential of phytoestrogens, *Expert opinion on investigational drugs*, 9 (2000) 1829-1840. <https://doi.org/10.1517/13543784.9.8.1829>.
- [132] L.G. Korkina, C. De Luca, V.A. Kostyuk, S. Pastore, Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments, *Curr. Med. Chem.* 16 (2009) 3943-3965. <https://doi.org/10.2174/092986709789352312>.
- [133] R.M. de Lima, A.C. Dos Reis, A.A. de Menezes, J.V. Santos, J.W. Filho, J.R. Ferreira, M.V. de Alencar, A.M. da Mata, I.N. Khan, A. Islam, S.J. Uddin, Protective and therapeutic potential of ginger (*Zingiber officinale*) extract and [6]-gingerol in cancer: A comprehensive review, *Phytother. Res.* 32 (2018) 1885-1907. <https://doi.org/10.1002/ptr.6134>.
- [134] C.H. Jeong, A.M. Bode, A. Pugliese, Y.Y. Cho, H.G. Kim, J.H. Shim, Y.J. Jeon, H. Li, H. Jiang, Z. Dong, Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase, *Cancer res.* 69 (2009) 5584-5591. <https://doi.org/10.1158/0008-5472>.
- [135] H.S. Lee, E.Y. Seo, N.E. Kang, W.K. Kim, [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells, *The Journal of nutritional biochemistry*. May 19 (2008) 313-319. <https://doi.org/10.1016/j.jnutbio.2007.05.008>.
- [136] M.Y. Mboge, B.P. Mahon, R. McKenna, S.C. Frost, Carbonic anhydrases: role in pH control and cancer, *Metabolites*. 8 (2018) 19. <https://doi.org/10.3390/metabo8010019>.
- [137] J.C. Tapia, I. Niechi, Endothelin-converting enzyme-1 in cancer aggressiveness, *Cancer Lett.* 452 (2019) 152-157. <https://doi.org/10.1016/j.canlet.2019.03.033>.

- [138] C. van den Hoogen, G. van der Horst, H. Cheung, J.T. Buijs, R.C. Pelger, G. van der Pluijm, The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis, *Clin. Exp. Metastasis*. 28 (2011) 615-625. <https://doi.org/10.1007/s10585-011-9395-7>
- [139] J.H. Kang, S.H. Lee, D. Hong, J.S. Lee, H.S. Ahn, J.H. Ahn, T.W. Seong, C.H. Lee, H. Jang, K.M. Hong, C. Lee, Aldehyde dehydrogenase is used by cancer cells for energy metabolism, *Exp. Mol. Med.* 48 (2016) e272. <https://doi.org/10.1038/emm.2016.103>.
- [140] J. Han, Q. Shen, Targeting γ -secretase in breast cancer, *Breast Cancer: Targets and Therapy*. 4 (2012) 83. <https://doi.org/10.2147/BCTT.S26437>.
- [141] J. R. Wang, W. J. Gan, X. M. Li, Y.Y. Zhao, Y. Li, X. X. Lu, J.M. Li, H. Wu, () Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin, *Carcinogenesis*. 35 (2014) 2474-2484. <https://doi.org/10.1093/carcin/bgu157>.
- [142] X. Ding, D.R. Yang, S.O. Lee, Y.L. Chen, L. Xia, S.J. Lin, S. Yu, Y.J. Niu, G. Li, C. Chang, TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling, *Int. J. Cancer*. 136 (2015) 955-964. <https://doi.org/10.1002/ijc.29049>.
- [143] S. Fan, Y. Liao, C. Liu, Q. Huang, H. Liang, B. Ai, S. Fu, S. Zhou, Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer, *Oncotarget*. 8 (2017) 56443-56459. <https://doi.org/10.18632/oncotarget.16992>.
- [144] H. Huang, K. Wu, J. Ma, Y. Du, C. Cao, Y. Nie, Dopamine D2 receptor suppresses gastric cancer cell invasion and migration via inhibition of EGFR/AKT/MMP-13 pathway. *International immunopharmacology*, 39 (2016) 113-120. <https://doi.org/10.1016/j.intimp.2016.07.002>.
- [145] B. Wei, J. Wang, P. Bourne, Q. Yang, D. Hicks, H. Bu, P. Tang, Bone metastasis is strongly associated with estrogen receptor–positive/progesterone receptor–negative breast carcinomas. *Hum. Pathol.* 39 (2008) 1809-1815. <https://doi.org/10.1016/j.humpath.2008.05.010>.

- [146] Y. Vugmeyster, J. Harrold, X. Xu, (2012) Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions, *AAPS J.* 14 (2012) 714-727. <https://doi.org/10.1208/s12248-012-9385-y>.
- [147] F Qu, J. Zhou, Chinese medicinal herbs in relieving perimenopausal depression: a randomized, placebo-controlled trial, *Maturitas*, 63 (2009) S114. [https://doi.org/10.1016/S0378-5122\(09\)70456-6](https://doi.org/10.1016/S0378-5122(09)70456-6).
- [148] K.Y. Mumcuoglu, S. Magdassi, J. Miller, F. Ben-Ishai, G. Zentner, V. Helbin, F. Kahana, A. Ingber, Repellency of Citronella for Head Lice: Double-Blind, Randomized Trial of Efficacy and Safety, *Isr. Med. Assoc. J.* 6 (2004) 756-759.
- [149] S Wang, C. Zhang, G. Yang, Y. Yang, Biological properties of 6-gingerol: a brief review, *Nat. Prod. Commun.* 9 (2014). <https://doi.org/10.1177/1934578X1400900736>
- [150] M.F. Nagoor Meeran, S.N. Goyal, K. Suchal, C Sharma, C.R. Patil, S.K. Ojha, Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: a pentacyclic triterpenoid of therapeutic promise, *Frontiers in pharmacology*. 9 (2018) 892. <https://doi.org/10.3389/fphar.2018.00892>.
- [151] A. Hospital, J.R. Goñi, M. Orozco, J.L. Gelpí, Molecular dynamics simulations: advances and applications, *Adv. Appl. Bioinform. Chem.* 8 (2015) 37–47. <https://doi.org/10.2147/AABC.S70333>.
- [152] N.B. Finnerup, N. Attal, S. Haroutounian, E McNicol, R. Baron, R.H. Dworkin, I. Gilron, M. Haanpää, P. Hansson, T.S. Jensen, P.R. Kamerman, Pharmacotherapy for neuropathic pain in adults: A systemic review and meta-analysis. *Lancet Neurol.* 14 (2015) 163-73. [https://doi.org/10.1016/S1474-4422\(14\)70251-0](https://doi.org/10.1016/S1474-4422(14)70251-0).
- [153] R.B. Raffa, E. Friderichs, The basic science aspect of tramadol hydrochloride, *Pain Rev.* 3 (1996) 249–271.
- [154] K. Kota, A. Brufsky, S. Oesterreich, A. Lee, Estradiol as a targeted, late-line therapy in metastatic breast cancer with estrogen receptor amplification, *Cureus.* 9 (2017) e1434. <https://doi.org/10.7759/cureus.1434>.
- [155] R. Benamouzig, B. Uzzan, A. Martin, J. Deyra, J. Little, B. Girard, S. Chaussade, Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention, *Gut.* 59 (2010) 622–629. <http://dx.doi.org/10.1136/gut.2008.175406>.

- [156] J.L. Yang, Y. Han, Y.Q. Zhou, The role of Bcl-2 family in the apoptosis of human small cell lung cancer A549 cells induced by aspirin, *Guangdong Med. J.* 11 (2010) 1389–1391.
- [157] H. Uchida, T. Maruyama, M. Ono, K. Ohta, T. Kajitani, H. Masuda, T. Nagashima, T. Arase, H. Asada, Y. Yoshimura, Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodeilin. *Endocrinol.* 148 (2007) 896–902. <https://doi.org/10.1210/en.2006-0896>.
- [158] G.V. Skuladottir, R. Heidarsdottir, D.O. Arnar, B. Torfason, V. Edvardsson, G. Gottskalksson, R. Palsson, O.S. Indridason, Plasma n-3 and n-6 fatty acids and the incidence of atrial fibrillation following coronary artery bypass graft surgery, *Eur. J. Clin. Invest.* 41 (2011) 995–1003. <https://doi.org/10.1111/j.1365-2362.2011.02497>.
- [159] M.E. Lippman, C.K. Osborne, R. Knazek, N. Young, In vitro model systems for the study of hormone-dependent human breast cancer, *New Engl. J. Med.* 296 (1977) 154-159. <https://doi.org/10.1056/NEJM197701202960307>.
- [160] K.F. Azim, M. Hasan, M.N. Hossain, S.R. Somana. Immunoinformatics approaches for designing a novel multi epitope peptide vaccine against human norovirus (Norwalk virus). *Infect. Genet. Evol.* 74 (2019) 103936.
- [161] M. Hasan, , K.F. Azim, A.S. Imran, I.M. Chowdhury, S.R.A. Urme, M.S.A Parvez, ... & S.S.U. Ahmed. Comprehensive Genome Based Analysis of *Vibrio parahaemolyticus* for Identifying Novel Drug and Vaccine Molecules: Subtractive Proteomics and Vaccinomics Approach. *PlosOne* 15 (2020) e0237181.
- [162] M.R.N. Akhand, K.F. Azim, M.A. Moli, M. Hasan. Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine. *Infect. Genet. Evol.* 85 (2020) 104517.

Tables

Table 1: List of metastasis-associated proteins with their identities and functions

Protein Name	Uniprot ID	NCBI ID	Function	References
Metastasis-associated protein 1 (MTA1)	Q13330	NP_004680	<ul style="list-style-type: none"> • Part of histone-deacetylase multiprotein complex (NuRD) • Transcriptional co-repressor of BRCA1, ESR1, TFF1 and CDKN1A • Transcriptional co-activator of BCAS3, PAX5 and SUMO2, independent of the NuRD complex • Stimulates the expression of WNT1 by inhibiting expression of transcriptional co-repressor SIX3 • Regulates p53-dependent DNA repair following genotoxic stress • Regulates p53-dependent DNA repair • Plays vital role in tumorigenesis, tumor invasion and metastasis. • Regulates de-acetylation of ARNTL/BMAL1 and de-represses CRY1-mediated transcription • Promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation 	[10, 11, 12, 13, 14, 15]
Metastasis-associated protein 2 (MTA2)	O94776	NP_004730	<ul style="list-style-type: none"> • Might be involved in the regulation of gene expression as repressor and activator • Covalent modification of histone 	[16]
Metastasis-associated protein 3 (MTA3)	Q9BTC8	NP_001317371	<ul style="list-style-type: none"> • Maintenance of normal epithelial architecture through repression of SNAIL transcription in a histone deacetylase-dependent manner • Regulation of E-cadherin levels • Contributes to transcriptional repression by BCL6 	[17, 18]

Table 2: Class, identity, source and function of plant metabolites used in this study

Plant Metabolites	Pubchem CID	formula	Chemical Class	Plant Source	Activities	References
Allicin	65036	$C_6H_{10}OS_2$	S-containing compound	<i>Allium sativum</i>	Antimicrobial, antiviral Antioxidant, anti-cancer activity	[35]
Allylpropyl disulfide	16591	$C_6H_{12}S_2$	Allyl sulfur compound	<i>Allium cepa</i>	Prevents irregular heart-beat, abnormal blood pressure, coronary heart disease, arteriosclerosis, cancers, bronchitis, dry cough and blood clots	[36]
Andrographolide	5318517	$C_{20}H_{30}O_5$	Diterpenoid labdane	<i>Andrographis paniculata</i>	Antioxidant, anti-inflammatory and anti-cancer	[37]
Apigenin	5280443	$C_{15}H_{10}O_5$	Flavonoids	<i>Passiflora foetida</i>	Active against cancer, diabetes, depression & Alzheimer's disease,	[38]
Aristolochic acid	2236	$C_{17}H_{11}NO_7$	Monocarboxylic acid	<i>Aristolochia alba</i>	Anthelmintic, anti-inflammatory	[39]
Ascorbic acid	54670067	$C_6H_8O_6$	Dihydrofurans	<i>Citrus aurantifolia</i>	Anti-malaria	[40]
Asiatic acid	119034	$C_{30}H_{48}O_5$	Aglycone type pentacyclic diterpenoids	<i>Centella asiatica</i>	Antioxidant, antitumor, cardioprotective, anti-inflammatory, neuroprotective,	[41]
Avicularin	5490064	$C_{20}H_{18}O_{11}$	quercetin-3-O-arabinofuranoside (flavonoid)	<i>Lespedeza cuneata</i>	anti-inflammatory, antioxidant, hepatoprotective activity	[42]
Camphene	6616	$C_{10}H_{16}$	Prenol lipids	<i>Cymbopogon citrates</i>	Anti-malaria	[40]
Capsaicin	1548943	$C_{18}H_{27}NO_3$	Alkaloid	<i>Capsicum genus</i>	Pruritis, pain relief, non-steroidal anti-inflammatory drug	[43]
Chavibetol	596375	$C_{10}H_{12}O_2$	Phenylpropanoid	Piper betle	immunomodulatory, radical scavenging	[44]
Chavicine	1548912	$C_{17}H_{19}NO_3$	Alkaloids	<i>Piper nigrum</i>	Anti-tumorigenic, immune stimulatory, stomachic, carminative	[45]
Chrysoeriol	5280666	$C_{16}H_{12}O_6$	Flavonoids	<i>Passiflora foetida</i>	Antispasmodic, antibacterial,	[46]

					antihypertension, antiproliferative activity on human breast adenocarcinoma	
Cinnamic acid	444539	C ₉ H ₈ O ₂	Aromatic carboxylic acids	<i>Cinnamomum species</i>	Antibacterial, antifungal, antimalarial	[47]
Citronellal	7794	C ₁₀ H ₁₈ O	Prenol lipids	<i>Cymbopogon citrates</i>	Anti-malaria	[40]
Cianidanol	9064	C ₁₅ H ₁₄ O ₆	Flavonoids	<i>Ocimum gratissimum</i>	Antimicrobial, antioxidant, prevent the formation of oxidized Low-density Lipoprotein (LDL)	[48, 49, 50]
Cleomsclosin B	156875	C ₂₀ H ₁₈ O ₈	Coumarinoli gnoid	<i>Cleome viscosa</i>	Antiscorbutic, anthelmintic	[39]
Coumadin	54678486	C ₁₉ H ₁₆ O ₄	Coumarins and derivatives	<i>Sidaacuta</i>	Antipyretic and has inhibitory activity against disease causing bacteria	[51]
Curcumin	969516	C ₂₁ H ₂₀ O ₆	Polyphenolic compound	<i>Curcuma longa</i>	antibacterial, anti-inflammatory antiviral, antioxidant, anti-arthritis & anti-cancer activity	[52]
Dihydromorin	5458714	C ₁₅ H ₁₂ O ₇	Flavanonols	<i>Artocarpusheterophyllum</i>	Anti-ulcer	[53]
Eugenol	3314	C ₁₀ H ₁₂ O ₂	Phenylpropenoid	<i>Ocimumtenuiflorum, Eugenia caryophyllata</i>	antimicrobial, anti-inflammatory, analgesic and antioxidant	[54]
Flavylum	145858	C ₁₅ H ₁₁ O	Flavonoids	<i>Mallotus oppositifolius</i>	Anti-malarial and inhibits fungal growth	[55]
Galangin	5281616	C ₁₅ H ₁₀ O ₅	Flavonol	Honey, <i>Alpiniaofficinorum</i> , propolis	Anti-cancer, anti-mutagenic, anti-oxidative, radical scavenging etc.	[56]
Gentisic acid	3469	C ₇ H ₆ O ₄	Phenolic acid	<i>Gentiana, Citrus, H. rosa-sinensis, S. indicum</i>	Antioxidant, neuroprotective, antiinflammatory, hepatoprotective, antimicrobial activities	[57]
Geraniol	637566	C ₁₀ H ₁₈ O	Prenol lipids	<i>Cymbopogon citrates</i>	Anti-malaria	[40]
Guajaverin	5481224	C ₂₀ H ₁₈ O ₁₁	Flavonoid	<i>Psidiumguayana</i>	Anti-plaque activity	[58]
Gingerol	442793	C ₁₇ H ₂₆ O ₄	Phenols	<i>Zingiber officinale</i>	Prevents chilblains and circulatory problems,	[36]

					highly antiseptic, immune-stimulatory, inhibits blood clotting	
Hydrocyanic acid	768	CHN	Organo-nitrogen compounds	<i>Cryptolopsissan guinolenta</i>	Anti-tumor, anti-inflammatory	[58]
Isoflavone	72304	C ₁₅ H ₁₀ O ₂	Isoflavonoid s	<i>Ocimum gratissimum</i>	Prevents breast cancer & fat accumulation, anti-oxidant, antimicrobial, cardio-protective	[48, 49, 50]
Kaempferol	5280863	C ₁₅ H ₁₀ O ₆	Flavonoid aglycone	Vegetable and fruit	Anti-inflammatory, antioxidant, antidiabetic cardioprotective,	[59]
Luteolin	5280445	C ₁₅ H ₁₀ O ₆	Flavonoid	Carrots, celery peppers, olive peppermint	Anticancer, antioxidant, antimicrobial, anti-inflammatory	[60]
Myrcene	31253	C ₁₀ H ₁₆	Prenol lipids	<i>Piper nigrum</i>	immune stimulatory, carminative, anti-inflammatory, anti-oxidant	[45]
Norartocarpeti	5481970	C ₁₅ H ₁₀ O ₆	Flavonoids	<i>Artocarpushet erophyllus</i>	Anti-ulcer	[53]
Paucine	5280559	C ₁₃ H ₁₈ N ₂ O	Phenols	<i>Pentacletha macrophylla</i>	Anticarcinogenic	[61]
Piperic acid	5370536	C ₁₂ H ₁₀ O ₄	Alkaloid	<i>Piper nigrum</i>	No known function	[62]
Piperine	638024	C ₁₇ H ₁₉ N O ₃	Alkaloid	<i>Piper nigrum</i>	Anticancer, antimalarial antimicrobial.	[62]
Procyanidin	107876	C ₃₀ H ₂₆ O ₁₃	Flavonoids	<i>Adansoniadigitata</i>	Anti- inflammation	[63]
Quercetine	5280343	C ₁₅ H ₁₀ O ₇	Flavonoid	Diverse plant species	Antioxidant, cardiovascular, antiviral, anticancer, antimicrobial	[64]
Quinine	3034034	C ₂₀ H ₂₄ N ₂ O ₂	Cinchona alkaloids	<i>Azadirachtain dica</i>	Anti malaria, insecticide	[53]
Reserpine	5770	C ₃₃ H ₄₀ N ₂ O ₉	Yohimbine alkaloids	<i>Rauwolfia vomitoria</i>	Antihypertensive	[65, 66]
Riboflavin	493570	C ₁₇ H ₂₀ N ₄ O ₆	Pteridines derivatives	<i>Moringa oleifera</i>	Antioxidants, antimicrobial	[40]
Steppogenin	21596130	C ₁₅ H ₁₂ O ₆	Flavonoids	<i>Artocarpushet erophyllus</i>	Anti-ulcer	[53]
Swertinin	5491517	C ₁₅ H ₁₂ O ₆	Secoiridoid	<i>Swertiachirata</i>	Role in pharmacological	[67]

			glycoside		activities	
Thymoquinone	10281	C ₁₀ H ₁₂ O ₂	Monoterpene	<i>Nigella sativa</i>	Anti-oxidant and anti-inflammatory properties, Anti-microbial, Anti-arthritis, anti-cancer efficacy	[68]
Venilin	1183	C ₈ H ₈ O ₃	Phenols	<i>Vanilla planifolia</i>	Antimicrobial activities, Antifungal activities, Antioxidant and antimutagenic properties.	[69, 70]
Vincamine	15376	C ₂₁ H ₂₆ N ₂ O ₃	Alkaloid	<i>Catharanthus roseus</i> , <i>Vinca minor</i>	Cerebral disorders, antiulcer activity, cerebrovascular insufficiencies	[71]
Vitexin	5280441	C ₂₁ H ₂₀ O ₁₀	Apigenin flavone glucoside	<i>Crataegus species</i>	Anti-inflammatory effects, anti-oxidant effects, anti-carcinogenic effects, anti-viral effects	[72]
Withaferin	265237	C ₂₈ H ₃₈ O ₆	Steroidal lactone	<i>Withania somnifera</i>	Anti-cancer, adaptogenic, anti-stress, anti-inflammatory, anti-tumor, cardioprotective, and neuroprotective	[73]
Yohimbine	8969	C ₂₁ H ₂₆ N ₂ O ₃	Yohimbine alkaloids	<i>Rauwolfia vomitoria</i>	Antihypertensive	[65, 66]
Zingiberene	92776	C ₁₅ H ₂₄	Isoprenoids	Zingiber Officinale	Anti-ulcer, antibacterial, cytotoxic effect	[74]

Table 3: Physicochemical property analysis of MTA proteins

Proteins	Formula	Molecular weight	p ^I	Extinction coefficient	Half life	Aliphatic index	GRAVY
MTA 1	C ₃₅₆₅ H ₅₆₅₈ N ₁₀₃₂ O ₁₀₅₅ S ₂₉	80786.16	9.34	0.1%	30 hours (mammalian reticulocytes, <i>in vitro</i>) >10 hours (<i>E. coli</i> , <i>in vivo</i>)	75.48	-0.617
MTA 2	C ₃₃₀₃ H ₅₃₀₃ N ₉₆₉ O ₉₆₉ S ₂₉	75023.09	9.70	0.1%	30 hours (mammalian reticulocytes, <i>in vitro</i>). >10 hours (<i>E. coli</i> , <i>in vivo</i>).	77.19	-0.528
MTA 3	C ₂₉₈₂ H ₄₆₉₃ N ₈₃₇ O ₉₀₀ S ₂₆	67503.69	8.80	0.1%	30 hours (mammalian reticulocytes, <i>in vitro</i>) >10 hours (<i>E. coli</i> , <i>in vivo</i>).	74.75	-0.541

Table 4: Functional domains and motif analysis of MTA proteins

Protein	Pfam	Position (E-value)	Description
MTA1	MTA_R1	464..541 (3.9e-34) 658..690 (0.52)	PF17226, MTA R1 domain
	BAH	4..164 (1.3e-35)	PF01426, BAH domain
	ELM2	167..219 (1.7e-12)	PF01448, ELM2 domain
	GATA	393..429 (2e-09)	PF00320, GATA zinc finger
	Myb_DNA-binding	287..33 (6.5e-06)	PF00249, Myb-like DNA-binding domain
	Myb_DNA-bind_7	283..314 (0.0079)	PF15963, Myb DNA-binding like
MTA2	MTA_R1	448..524 (4.4e-28)	PF17226, MTA R1 domain
	BAH	4..143 (2.9e-28)	PF01426, BAH domain
	ELM2	147..198(4.9e-15)	PF01448, ELM2 domain
	GATA	367..403 (2.6e-11)	PF00320, GATA zinc finger
	Myb_DNA-binding	267..311 (0.00011)	PF00249, Myb-like DNA-binding domain
	Myb_DNA-bind_7	263..294 (0.031)	PF15963, Myb DNA-binding like
	Cytochrom_c3_2	362..393 (0.39)	PF14537, Cytochrome c3
MTA3	BAH	4..147 (1.9e-31)	PF01426, BAH domain
	MTA_R1	461..537 (1.7e-28)	PF17226, MTA R1 domain
	ELM2	150..201 (1.7e-15)	PF01448, ELM2 domain
	GATA	379..415 (4e-09)	PF00320, GATA zinc finger
	Myb_DNA-binding	270..314 (1.8e-05)	PF00249, Myb-like DNA-binding domain
	Myb_DNA-bind_7	266..297 (0.016)	PF15963, Myb DNA-binding like

Table 5: Docking results of top metabolites against MTA proteins

<i>Macromolecules</i>	<i>Ligands</i>	<i>Global energy</i> (kcal/mol)	<i>Attractive VdW</i>	<i>ACE</i>	<i>Binding sites</i>
MTA 1	Isoflavone	-41.78	-23.19	-8.06	Asp94, Leu95, Pro96, Glu97, Leu99, Leu108, Phe109, Leu110, Ser111, Arg112, Gln113, Leu114, Glu115, Ser116, Arg123
	Gingerol	-51.23	-22.36	-11.92	Gln400, Pro433, Thr434, Asp437, His498, Tyr500, Pro629, Lys631, Val632, Arg633
	Citronellal	-48.32	-26.00	-10.39	Thr398, Thr399, Gln400, Ser401, Trp 404, Pro433, Asp437, Arg445, His498, Pro499, Tyr500, Pro629, Lys631, Val632, Arg633
	Asiatic Acid	-48.44	-23.80	12.64	Leu453, Pro454, Ser457, Leu473, Thr475, Thr476, Thr479, Ala506, Ala507, Ile508, Lys509, Ala510, Glu511, Asp592
	Control (Metarrestin)	-25.00	-9.99	-6.48	Asp163, Lys164, Phe213, Val216, Arg234, Gln235, Pro236, Ser237, Met240, Asp306, Asp309
MTA 2	Isoflavone	-54.70	-25.38	-15.65	Gln333, Gln377, Lys363, Trp378, Tyr379, Ala380, Trp381
	Gingerol	-52.71	-24.66	-13.83	Gln305, Ile336, Thr338, Thr340, Gly569, Val570, Pro571, Phe572, Leu616, Arg617, Lys618, Ala619, Thr621
	Citronellal	-44.09	-16.99	-15.35	Val334, Ala359, Gly360, Phe361, Gln362, Gln387, Cys388, Arg389, Leu390, Cys391, Tyr397, His421, Ser422, His425, Asp600,
	Asiatic Acid	-49.77	-21.10	-17.91	Tyr153, Gln154, Glu163, Gly164, Ser166, Asp167, Arg169, Met174, Asp286, Lys298, Ser302, Ile303, Ala615, Lys618, Ala619,

MTA 3					Leu620
	Control (Metarrestin)	-28.35	-11.13	-7.85	Gln333, Tyr335, Gln362, Lys363, Gly364, Leu365, Trp378, Pro383
	Isoflavone	-69.20	-29.52	-18.74	Phe290, Ile293, Arg294, Glu425, Lys426, Leu303, Ser430, Pro431, Thr433, Glu434, Asp435, Pro436, Gln448, Gly449, Met450, Val452
	Gingerol	-48.02	-22.08	-13.47	Tyr13, Asn454, Thr455, Glu508, Tyr509, Ala510, Asp511, Arg512, Leu574, Gly575, Lys576,
	Citronellal	-54.84	-24.04	-15.04	Lys83, His84, Gln85, Leu86, Lys87, Glu90, Gly148, Glu149, Val152, Ala158, Ile160, Ser272, Ala276
	Asiatic Acid	-53.22	-24.66	-4.20	Tyr13, Arg453, Asn454, Thr455, Gly456, Pro458, His471, Tyr474, Val498, Ile505, Glu508, Tyr509,
	Control(Metarrestin)	-26.26	-9.50	-7.69	Lys147, Gly148, Ile150, Arg151, Val152, Arg265, Met268, Glu269

Table 6: ADME analysis of top drug candidates

Parameters		Top Inhibitors of Metastasis Tumour Antigen Protein			
		<i>Isoflavone</i>	<i>Asiatic Acid</i>	<i>Citronella</i>	<i>Gingerol</i>
Physicochemical parameters	Formula	C15H10O2	C30H48O5	C10H18O	C17H26O4
	Molecular weight	222.24 g/mol	488.70 g/mol	154.25 g/mol	294.39 g/mol
	H-bond acceptors	2	5	1	4
	No. H-bond donors	0	4	0	2
	Molar Refractivity	67.92	139.24	49.91	84.55
	TPSA	30.21 Å ²	97.99 Å ²	17.07 Å ²	66.76 Å ²
Lipophilicity	Log $P_{o/w}$ (iLOGP)	2.51	2.89	2.49	3.48
	Log $P_{o/w}$ (XLOGP3)	3.18	5.70	3.83	2.76
	Log $P_{o/w}$ (WLOGP)	3.46	5.03	2.96	3.23
	Log $P_{o/w}$ (MLOGP)	2.27	4.14	2.59	2.14
	Log $P_{o/w}$ (SILICOS-IT)	4.04	3.96	2.82	4.04
	Consensus Log $P_{o/w}$	3.09	4.34	2.94	3.13
Pharmacokinetic s	GI absorption	High	High	High	High
	BBB permeant	No	No	Yes	No
	P-gp substrate	No	Yes	No	No
	CYP1A2 inhibitor	Yes	No	No	Yes
	CYP2C19 inhibitor	No	No	No	No
	CYP2C9 inhibitor	No	No	No	No
	CYP2D6 inhibitor	No	No	No	Yes
	CYP3A4 inhibitor	No	No	No	No
Water Solubility	Log K_p (skin permeation)	-5.40 cm/s	-5.23 cm/s	-4.52 cm/s	-6.14 cm/s
	Log S (ESOL)	-3.85	-6.33	-2.88	-2.96
	Solubility (mg/ml)	3.13e-02	2.29e-04	2.04e-01	3.26e-01
	Class	Soluble	Poorly soluble	Soluble	Soluble
	Log S (SILICOS-IT)	-6.13	-4.28	-2.33	-4.58
	Solubility (mg/ml)	1.63e-04	2.59e-02	7.26e-01	7.65e-03
Medicinal Chemistry	Class	Poorly Soluble	Moderately soluble	Soluble	Moderately Soluble
	Leadlikeness	Yes; 0 violation	No; 2 violations: MW>350, XLOGP3>3.5	No; 2 violations: MW<250, XLOGP3>3.5	No; 1 violation: Rotors>7
	Bioavailability	0.55	0.56	0.55	0.55
	PAINS	0 alert	0 alert	0 alert	0 alert
	Synthetic accessibility	2.82	6.56	2.57	2.81

Table 7: Toxicity pattern analysis of top drug candidates

Toxicity Parameters	Top drug candidates			
	Isoflavone	Gingerol	Citronellal	Asiatic Acid
AMES Test	No	No	Yes	No
Max. Tolerated Dose (log mg/kg/day)	0.107	0.635	0.865	0.078
hERG I inhibitor	No	No	No	No
hERG II inhibitors	No	No	No	No
Oral Rat Acute Toxicity, LD50 (mol/kg)	1.726	1.958	2.482	2.592
Oral Rat Chronic Toxicity, LOAEL (log mg/kg_bw/day)	0.99	1.631	0.391	0.575
Hepatotoxicity	No	No	No	No
Skin Sensitisation	No	No	No	No
<i>T. pyriformis</i> Toxicity (log µg/L)	1.244	1.487	0.57	0.285
Minnow Toxicity (log mM)	0.603	0.966	4.555	1.106

Table 8: Predicted drug targets for Isoflavone, Gingerol, Citronellal and Asiatic acid

Metabolites	Drug Targets	Common Name	Uniprot ID	ChEMBL ID	Target Class
Isoflavone	Monoamine oxidase B	MAOB	P27338	CHEMBL2039	Oxidoreductase
	Estrogen receptor β	ESR2	Q92731	CHEMBL242	Nuclear receptor
	Carbonic anhydrase XII	CA12	O43570	CHEMBL3242	Lyase
	Estrogen-related receptor α	ESRRA	P11474	CHEMBL3429	Nuclear receptor
	Estrogen-related receptor β	ESRRB	O95718	CHEMBL3751	Nuclear receptor
	Monoamine oxidase A	MAOA	P21397	CHEMBL1951	Oxidoreductase
	Carbonic anhydrase VII	CA7	P43166	CHEMBL2326	Lyase
	Carbonic anhydrase IV	CA4	P22748	CHEMBL3729	Lyase
	Estrogen receptor α	ESR1	P03372	CHEMBL206	Nuclear receptor
	Aldehyde dehydrogenase	ALDH2	P05091	CHEMBL1935	Oxidoreductase
	Estrogen receptor α	ESR1	P03372	CHEMBL206	Nuclear receptor
	Estrogen receptor α	ESR1	P03372	CHEMBL206	Nuclear receptor
Gingerol	Serotonin 1a (5-HT1a) receptor	HTR1A	P08908	CHEMBL214	A G protein-coupled receptor
	Arachidonate 5-lipoxygenase	ALOX5	P09917	CHEMBL215	Oxidoreductase
	mitogen-activated protein kinase kinase 1	MAP2K1	Q02750	CHEMBL3587	Kinase
	Acyl-protein thioesterase 1	LYPLA1	O75608	CHEMBL1681631	Enzyme
	Acyl-protein thioesterase 2	LYPLA2	O95372	CHEMBL1932891	Enzyme
	Peroxisome proliferator-activated receptor γ	PPARG	P37231	CHEMBL235	Nuclear receptor
	Carbonic anhydrase II	CA2	P00918	CHEMBL205	Lyase
	Carbonic anhydrase IV	CA4	P22748	CHEMBL3729	Lyase
	Endothelin-converting enzyme 1	ECE1	P42892	CHEMBL4791	Protease
Citronella	Cytochrome P450 19A1	CYP19A1	P11511	CHEMBL1978	Cytochrome P450

	Steroid 5- α -reductase 1	SRD5A1	P18405	CHEMBL1787	Oxidoreductase
	Alcohol dehydrogenase α chain	ADH1A	P07327	CHEMBL1970	Oxidoreductase
	Alcohol dehydrogenase β chain	ADH1B	P00325	CHEMBL3284	Oxidoreductase
	Alcohol dehydrogenase class IV	ADH7	P40394	CHEMBL3867	Enzyme
	Monoamine oxidase B	MAOB	P27338	CHEMBL2039	Oxidoreductase
	Progesterone receptor	PGR	P06401	CHEMBL208	Nuclear receptor
	Monoamine oxidase A	MAOA	P21397	CHEMBL1951	Oxidoreductase
	Cyclooxygenase-1	PTGS1	P23219	CHEMBL221	Oxidoreductase
	Aldehyde dehydrogenase 1A1	ALDH1A1	P00352	CHEMBL3577	Enzyme
	Cathepsin K	CTSK	P43235	CHEMBL268	Protease
	Cathepsin L	CTSL	P07711	CHEMBL3837	Protease
	Cathepsin (B and K)	CTSB	P07858	CHEMBL4072	Protease
	NAD-dependent deacetylase sirtuin 2	SIRT2	Q8IXJ6	CHEMBL4462	Eraser
	Alcohol dehydrogenase γ chain	ADH1C	P00326	CHEMBL3285	Oxidoreductase
	γ -secretase	PSEN2	P49810	CHEMBL2094135	Protease
	Peroxisome proliferator-activated receptor α	PPARA	Q07869	CHEMBL239	Nuclear receptor
	Cathepsin D	CTSD	P07339	CHEMBL2581	Protease
Asiatic acid	Aldo-keto reductase family 1 member B10	AKR1B10	O60218	CHEMBL5983	Enzyme
	Nuclear receptor ROR- γ	RORC	P51449	CHEMBL1741186	Nuclear receptor
	Estrogen-related receptor α	ESRRA	P11474	CHEMBL3429	Nuclear receptor
	Estrogen-related receptor β	ESRRB	O95718	CHEMBL3751	Nuclear receptor
	Peroxisome proliferator-activated receptor γ	PPARG	P37231	CHEMBL235	Nuclear receptor

	Peroxisome proliferator-activated receptor α	PPARA	Q07869	CHEMBL239	Nuclear receptor
	Peroxisome proliferator-activated receptor δ	PPARD	Q03181	CHEMBL3979	Nuclear receptor
	Arachidonate 5-lipoxygenase	ALOX5	P09917	CHEMBL215	Oxidoreductase
	Cyclooxygenase-2	PTGS2	P35354	CHEMBL230	Oxidoreductase
	Cytochrome P450 19A1	CYP19A1	P11511	CHEMBL1978	Cytochrome P450

Table 9: Predicted synthetic analogs of top metabolites from DrugBank

Metabolites	Synthetic analogs	DrugBank id	Score	Status
Isoflavone	(1s)-1-(Phenoxymethyl)Propyl Methylphosphonochloridoate	DB08419	0.134	Experimental
Gingerol	Tramadol	DB00193	0.476	Approved
	Estradiol	DB00783	0.332	Approved
	Nabumetone	DB00461	0.235	Approved
	Estrone	DB00655	0.231	Approved
	Mestranol	DB01357	0.227	Approved
	Matairesinol	DB04200	0.511	Experimental
	3-(3,4-Dimethoxyphenyl)Propionic Acid	DB04208	0.485	Experimental
Citronella	Progesterone	DB00396	0.664	Approved
	Ethanolamine Oleate	DB06689	0.483	Approved
	Diethylcarbamazine	DB00711	0.329	Approved
	Dihomo-gamma-linolenic acid	DB00154	0.325	Approved
	Alpha-Linolenic Acid	DB00132	0.325	Approved
	4-Androstenedione	DB01536	0.806	Experimental
	19-norandrostenedione	DB01434	0.797	Experimental
	(R)-N-(1-Methyl-Hexyl)-Formamide	DB03061	0.562	Experimental
Asiatic acid	Hydrocortisone	DB00741	0.539	Approved
	Dinoprost Tromethamine	DB01160	0.510	Approved
	Medrysone	DB00253	0.455	Approved
	Ethanolamine Oleate	DB06689	0.392	Approved
	Methyltestosterone	DB06710	0.371	Approved
	Pregnenolone	DB02789	0.419	Experimental
	Oleic Acid	DB04224	0.392	Experimental
	Delta1-dihydrotestosterone	DB01481	0.371	Experimental

Figure legends

Figure 1: Predicted secondary structure of MTA1 (A), MTA2 (B) and MTA3 protein (C).

Figure 2: Predicted domains and motifs of MTA1 (A), MTA2 (B), MTA3 (C).

Figure 3: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA1 protein.

Figure 4: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA2 protein.

Figure 5: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA3 protein.

Figure 6: Predicted ligand binding pockets of MTA1 (A), MTA2 (B), MTA3(C) via CASTp.

Figure 7: Molecular interaction of gingerol with MTA1 protein (A), isoflavone with MTA 2 (B) and isoflavone with MTA3 protein (C).

Figure 8: Chemical structure and ADME analysis of top drug candidates; (A) gingerol, (B) isoflavone, (C) citronellal, (D) asiatic acid.

Figure 9: Predicted drug targets for gingerol (A), isoflavone (B), citronellal (C), asiatic acid (D).

Figure 10: Metapathway, NMA, Corelated residues and Hub % analysis of MTA1-gingerol complex (A), MTA2-isoflavone omplex (B), and MTA3-isoflavone complex (C).

Figure 11: The final models (represented as cartoons) showed minor fluctuations for MTA1 (A), and comparatively rigidness for MTA2 (D) and MTA3 (G). The contact atom maps (B, E, H) and fluctuation plots of MTA1 (C), MTA2 (F) and MTA3 (I) represent the fluctuations in the residues during simulation.

Figure 1: Predicted secondary structure of MTA1 (A), MTA2 (B) and MTA3 protein (C).

Figure 2: Predicted domains and motifs of MTA1 (A), MTA2 (B), MTA3 (C).

Figure 3: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA1 protein.

Figure 4: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA2 protein.

Figure 5: Homology modeling (A), quality factor (B), ramachandra plot assessment (C), amino acid Distribution plot (D), deformability (E), atom index (F), eigen value (G) of MTA3 protein.

Figure 6: Predicted ligand binding pockets of MTA1 (A), MTA2 (B), MTA3(C) via CASTp server

Figure 7: Molecular interaction of gingerol with MTA1 protein (A), isoflavone with MTA 2 (B) and isoflavone with MTA3 protein (C).

Figure 8: Chemical structure and ADME analysis of top drug candidates; (A) gingerol, (B) isoflavone, (C) citronellal, (D) asiatic acid.

Figure 9: Predicted drug targets for gingerol (A), isoflavone (B), citronellal (C), asiatic acid (D).

Figure 10: Metapathway, NMA, Correlated residues and Hub % analysis of MTA1-gingerol complex (A), MTA2-isoflavone complex (B), and MTA3-isoflavone complex (C).

Figure 11: The final models (represented as cartoons) showed minor fluctuations for MTA1 (A), and comparatively rigidity for MTA2 (D) and MTA3 (G). The contact atom maps (B, E, H) and fluctuation plots of MTA1 (C), MTA2 (F) and MTA3 (I) represent the fluctuations in the residues during simulation.